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 1 Abbreviations 
7AAD 7-Aminoactinomycin 
AH Armenian hamster 
APC Allophycocyanin 
APC H7 Allophycocyanin horizon 7 
BLM Bleomycin 
CCR Cc-motive chemokine receptor 
CXCR Cxc-motive chemokine receptor 
EDTA Ethylenediaminetetraacetic acid 
EMT Epithelial to mesenchyal transition 
FACS Fluorescence activated cell sorting 
FITC Fluorescinisothiocyanat 
FSC Forward scatter 
HRCT High resolution computed tomography 
IC Isotype control 
IgG Immunoglobulin G 
IIP Idiopathic interstitial pneumonia 
IL Interleukin 
ILD Interstitial lung disease 
ip intraperitoneal 
IPF Idiopathic pulmonary fibrosis 
It intratracheal 
iv Intravenous 
MCP-1 Macrophage chemoattractant protein 1 
MMP Matrix metallo proteinase 
NSIP Nonspecific interstitial pneumonia 
PB Pacific blue 
PBS Phosphate buffered saline 
PE Phycoerythin 
RB-ILD Respiratory bronchiolitis associated 
interstitial lung disease 
SSC Side scatter 
Tcm Central memory T cell 
Tem Effector memory T cell 
TGFβ Transforming growth factor β 
Th T helper cell 
tLT Tertiary lymphoid tissue 
Tnaive Naïve T cell 
Treg Regulatory T cell 
wt Wild type 
α-SMA α smooth muscle actin 
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2 Introduction 
 Interstitial lung diseases 2.1
 Classification 2.1.1
Interstitial lung diseases (ILD) are a group of diverse chronic inflammatory lung disorders 
which are characterized by restrictive impairment of lung function and diffuse lung 
infiltration (Figure 1). 
An important, although rare group of ILD are the idiopathic interstitial pneumonias (IIP), as 
some of them are extremely rapidly progressive and lead to death within less than 10 years 
following diagnosis. By definition, their origin is not known. Furthermore, there is no curative 
treatment available for most of them, and the standard anti-inflammatory strategies do not 
lead to a sufficient control of symptoms. The following will concentrate on IPF which 
presents the most frequent entity of IIPs. 
 
Figure 1 Classification of ILD and relative frequency of subgroups; modified from (1, 2); IPF: idiopathic 
pulmonary fibrosis; NSIP: nonspecific interstitial pneumonitis; RB-ILD: respiratory bronchiolitis associated 
interstitial lung disease; DIP: desquamative interstitial pneumonia; COP: cryptogenic organizing pneumonitis; 
AIP: acute interstitial pneumonia; LIP: lymphoid interstitial pneumonia 
 Idiopathic pulmonary fibrosis 2.1.2
 Clinical specifications 2.1.2.1
“Idiopathic pulmonary fibrosis is defined as a specific form of chronic, progressive fibrosing 
interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the 
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lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial 
pneumonia (UIP)” (ATS and ERS 2011 (3)). 
The median survival time of IPF is estimated to be 2 to 3 years from the day of diagnosis (4, 
5). A study from the USA estimated a prevalence of 14 to 42 per 100 000 persons and an 
incidence of 6.8 to 16 per 100 000 persons (6). Another study from the UK found a lower 
incidence of 4.6 per 100 000 people but observed an increase in incidence for the period 
between 1991 and 2003 (7). 
IPF patients present with unspecific symptoms like a chronic dry cough, dyspnea at exertion, 
and bibasilar crackles in the physical examination. Lung function tests show a restrictive 
pattern with a decreased vital capacity and impaired gas exchange. 
The clinical course of IPF is characterized either by a subacute or more rapid loss of lung 
function or by an intermittant disease course with phases of acute exacerbations, which 
eventually lead to a rapid respiratory failure and death (8, 9). 
The main diagnostic tool is the “high resolution computed tomography” (HRCT), which 
shows the typical UIP pattern, defined by the combination of basal subpleural reticular 
opacity, honeycombs and bonchiectasis (10, 11). 
If the radiological features are not sufficient to confirm the suspicion of IPF, the diagnostic is 
completed by the histopathologic evaluation of a surgical lung biopsy. The histologic UIP-
pattern is characterized by a heterogeneous appearance in lower magnifications, reflecting 
areas with different stages of fibrotic areas next to regions of normal lung parenchyma. In 
higher magnifications, fibrotic areas are marked by fibroblast foci and accumulation of 
collagen. The inflammatory reaction is represented by a patchy infiltrate of lymphocytes and 
plasma cells in combination with a hyperplasia of type II alveolar cells and bronchial 
epithelial cells. (1, 3, 12) 
None of the currently available treatment options provides a curative approach or even 
sufficient symptom control for the majority of affected patients. Immunosupressive therapy 
with corticoids or immunosuppressive drugs like azathioprine used for other interstitial lung 
diseases seem to have no beneficial effects in IPF. Uniquely for patients with acute 
exacerbations immunosupressive treatment could possibly decrease mortality (13). 
The ATS/ERS/JRS/ALAT guideline from 2011 recommeded a combination therapy with 
immunomodulators and acetylcysteine was for selected patients (3). Meanwhile, this 
recommendation was withdrawn, as a trial comparing the treatment with prednisone, 
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azathioprine and acetylcyteine versus acetylcysteine alone showed a higher risk for 
hospitalisation and death in the group treated with the combination therapy (14). 
The only curative approach in IPF is lung transplantation. However, due to the lack of donor 
organs and contraindications at the side of the patients it is only applicable to a very defined 
group of patients (15). In 2011 pirfenidone, the first drug specifically for the treatment of 
IPF, has been approved in the European Union. Patients treated with pirfenidone showed 
decreased loss of forced vital capacity (FVC) compared to patients receiving placebo, but the 
drug could not stop the disease progression (16, 17). Beneath these poor treatment options 
only symptomatic, supportive therapies like oxygen supplementation ot physical therapy 
reamain (3).  
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 Concepts of pathogenesis 2.1.2.2
As indicated by the word “idiopathic” the origin of IPF is unknown. Former concepts of 
pathogenesis assumed that IPF is a chronic inflammatory disease. The failure of 
immunosuppressive therapies let to another hypothesis which proposes repeated injuries of 
the alveolar epithelium being the starting point of the disease (18). Several risk factors were 
found to be often associated with IPF, such as smoking (19), environmental exposures like 
different types of dusts (20), chronic viral infections in particular herpes virus infection (21), 
and gastro oesophageal reflux (22). These factors might contribute to the initial lung injury, 
but up to now, none of them could be identified as the main factor for the development of 
IPF. 
As consequence of the chronic injury, the development of the fibrotic reaction is thought to 
be the result of impaired wound healing processes through the loss of basement membrane 
integrity (23). These processes are driven by different components of the lung tissue. A 
dysfunction of the alveolar epithelium leads to apoptosis of epithelial cells. Mesenchymal 
components lead to an overwhelming extracellular matrix production. Different cytokines 
secreted by epithelial and mesenchymal cells attract immune cells. 
Based on observations made in familial cases of IPF, the contribution of genetic alterations in 
the pathogenesis of IPF was suspected, but only a minority of patients presented similar 
mutations (24, 25). However, one common phenomenon found more frequently in sporadic 
and familial cases of IPF is a shortening of telomeres in peripheral blood leucocytes and 
alveolar epithelial cells. Interestingly, in the majority of these patients with sporadic IPF no 
mutation in the telomerase gene was found. This telomere shortening is thought to promote 
apoptosis of pulmonary epithelial cells, and could provide an explanation for the late onset 
of the disease (25-27). 
A dysregulation of matrix metallo proteinases (MMPs) activity seems to play a role in the 
destruction of the basement membrane and the imbalance of the tissue remodeling 
processes in the lung. MMP2 and MMP9, which degrade the collagen IV of the basement 
membrane, were overexpressed in lung tissue and BALF of patients with interstitial lung 
diseases (28). MMP7 was overexpressed in lung tissue of patients with pulmonary fibrosis 
and MMP7-/- mice were protected from pulmmonary fibrosis (29). 
A number of different cytokines and other mediators were identified as pro-fibrotic factors 
in interstitial lung diseases. Among these, TGFβ is one of the best characterized. It was found 
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to be involved in collagen production, epithelial cell apoptosis (30), epithelial to 
mesenchymal transition (EMT) (31, 32) and fibroblast differentiation into myofibroblasts 
(33). Myofibroblasts are suggested to be the source of the overwhelming extracellular matrix 
production in IPF. Their origin is not yet clarified. The concepts reach from 
transdifferentiation of resident fibroblasts over EMT (34) to recruitment of bone marrow 
derived mesenchymal stem cells (35). 
The contribution of the immune system to fibrogenesis is multifactorial. Besides many other 
cell types and pathways, T cells seem to play an important role in the pathogenesis of IPF. 
There is evidence that a Th2 polarized immune response has profibrotic effects, whereas a 
Th1 response might be antifibrotic (36). Furthermore, IL17 produced by Th17 and γδ T cells 
was found to have profibrotic effects in the early phase of bleomycin (BLM) induced fibrosis 
in mice (37). Mice overexpressing the Th2 cytokine IL13 showed spontanous subepithelial 
pulmonary fibrosis (38), while blocking of IL13 resulted in decreased fibrosis following 
Aspergillus fumigatus (39) or bleomycin challenge (40). IL13 might act via induction of TGFβ 
production in pulmonary epithelial cells and its activation (41). In mouse models, as well as 
in human disease, there are hints for a dominance of Th2 cytokines in pulmonary fibrosis 
(40, 42). However, this Th2 polarization is not uncontroversial since lung fibroblasts were 
shown to produce predominantly Th1 related cytokines (43). IFNγ, a cytokine produced by 
Th1 cells, as well as IL10, produced by Treg, were shown to have anti fibrotic effects (44-47). 
IL10 gene polymorphisms resulting in reduced IL10 production were found in IPF patients 
(48). In turn, IL10 delivery to the lung attenuates BLM induced pulmonary fibrosis in mice 
(46). 
These and many other processes finally lead to the owerwhelming matrix production and 
consequently to a thickening of the alveolar walls and a loss of the lung elasticity. 
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 The role of CCR2 in pulmonary fibrosis 2.2
CC-motive chemokine receptor 2 (CCR2) is a member of the group of seven transmembrane-
spanning G protein coupled chemokine receptors. It is constitutively expressed on 
macrophages and monocytes but also on lymphocyte subsets (49) and fibrocytes (50, 51). It 
binds the chemokines CCL2, 7, 8, 13 and 16 with CCL2, also known as monocyte 
chemoattractant protein-1 (MCP-1), being the major ligand. In turn, CCR2 is the only known 
receptor for CCL2 unlike most other chemokines that bind to multiple receptors (52). CCL2 is 
expressed by a variety of cell types like epithelial cells, including pulmonary epithelium (53), 
endothelial and smooth muscle cells (54), fibroblasts (55), and in particular macrophages 
(49). 
In peripheral blood of BALB/c mice CCR2 was expressed on approximately 5 to 15 % of CD4+ 
T cells and 2 to 8% of CD8+ T cells, but in inflamed tissue sites the percentage of CCR2 
expressing T cells increased up to 50 % (56). 
The diverse functions of the CCR2/CCL2 axis are not fully understood, yet. Classically, CCR2 is 
classified as pro-inflammatory chemokine receptor. Among others, it participates in 
leukocyte recruitment and T cell polarization (57, 58). 
The content of CCR2+ T cells was found increased in different chronic inflammatory disorders 
like Crohn’s disease (59), rheumatoid arthritis (60) or multiple sclerosis (61). In a mouse 
model of collagen induced arthritis CCR2+ T cells gained regulatory functions (62). 
There is evidence that the CCR2/CCL2 axis plays also a role in the pathogenesis of pulmonary 
fibrosis. CCR2 and its ligand are considered to have pro-fibrotic effects. In vitro studies 
showed that CCL2 promotes collagen deposition and production of TGFβ in fibroblasts (63). 
Furthermore, it induced fibrocyte proliferation and production of α-SMA in cultured 
fibrocytes of murine and human origin (51). In turn, fibroblasts from CCR2 knock-out mice 
showed less α-SMA production upon stimulation by TGFβ than those from wt mice (64). 
CCL2 was increased in the BALF of mice treated with BLM (65). CCR2 deficiency, as well as 
blockade of CCL2 resulted in attenuated bleomycin induced fibrosis in mice (64, 66). In the 
lungs of these mice, decreased levels of TGFβ and α-SMA mRNA were detected (64). 
Fibrocyte migration to the murine lung in response to FITC induced lung injury was 
dependent on CCR2, as CCR2 deficient mice showed lower fibrocyte migration to the lung, 
and thus were protected from FITC induced pulmonary fibrosis. However, the inflammatory 
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reaction was similar in CCR2+/+ and CCR2-/- mice (50, 66). Also, the expression of MMP2 and 
MMP9 was reduced in lung tissue from BLM treated CCR2-/- mice compared to wt (67).  
On the other hand, one study reported that mice transgenic for hCCL2 were protected from 
mortality after bleomycin induced fibrosis. Thus, they showed higher 
monocytes/macrophages and lymphocytes in BALF compared to wt mice, while the 
accumulation of neutrophils was restricted following BLM treatment. CCL2 transgenic mice 
deficient for CCR2 were not protected from pulmonary fibrosis, which indicated that the 
effect was dependent on CCR2 (65). The reason for the discrepancy of these results is not 
evident and needs further investigation, but these conflicting observations may strengthen 
the hypothesis of differential functions of the CCR2/CCL2 axis. 
CCL2 as well as CCR2+ T cell percentages were increased in children with different forms of 
ILDs (68). However, the role of these specific lymphocytes in the context of pulmonary 
fibrosis is not clear. Thus, it is unknown if they contribute to the pathogenesis of disease or, 
on the contrary, represent an unsuccessful attempt of the immune system to limit the 
disease. 
15 
3 Hypothesis and Aims 
As outlined above, there is evidence for an important role of CCR2 in ILD, but the specific 
contribution of CCR2+ T cells in the pathogenesis of ILD is unclear.  
In the present work, we hypothesize that, pulmonary CCR2+ T cells have specific functional 
properties. 
Therefore, the aim of this study was to perform a phenotypic characterization of pulmonary 
CCR2+ T cells using an animal model of bleomycin-induced pulmonary fibrosis. 
In particular, we asked: 
 
- How does the relative content of CCR2+ T cells change in the lung after bleomycin 
treatment? 
- What is the phenotype of pulmonary CCR2+ T cells in bleomycin induced fibrotic lung 
disease? 
- Are pulmonary CCR2+ T cells a naïve T cell population or do they express markers of 
effector or central memory T cells? 
- Which chemokine receptors are co-expressed on CCR2+ T cells? 
- Are there changes of the phenotype of spleen T cells, as indicator of a systemic T cell 
response after bleomycin treatment? 
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4 Materials and Methods 
 Materials 4.1
 Equipment 4.1.1
Balance XS205 Mettler Toledo, Gießen, Germany 
Centrifuge Mikro 200R Hettich, Tuttlingen, Germany 
Centrifuge Rotina 420R Hettich, Tuttlingen, Germany 
Eppendorf mini spin plus Eppendorf, Hamburg, Germany 
Forceps Fine Science Tools , Heidelberg, Germany 
High pressure syringe Penn Century, Wyndmoor, USAa 
LSR II Flow Cytometer BD Biosciences, San Jose, USA 
Microm EC350-2 embedding station Thermo scientific, Walldorf, Germany 
Microm STP 420D- tissue processor Thermo scientific, Walldorf, Germany 
Microscope Axiovert 40C Zeiss, Oberkochen, Germany 
Microtom Hyrax 55 Zeiss, Oberkochen, Germany 
Mirax SCAN Zeiss, Oberkochen, Germany 
Multipette stream Eppendorf, Hamburg, Germany 
Neubauer Improved 0.1 mm depth Brand, Wertheim, Germany 
Pipettes Research plus  Eppendorf, Hamburg, Germany 
Scissors Fine Science Tools , Heidelberg, Germany 
 
 Software 4.1.2
Excel 2010 Microsoft, Redmond, USA 
FACSDiva Version 6.1.3 BD Biosciences, San Jose, USA 
GraphPad Prism Version 5.00 GraphPad Software, San Diego USA 
Mirax scan Zeiss, Oberkochen, Germany 
Mirax viewer Zeiss, Oberkochen, Germany 
Word 2010 Microsoft, Redmond, USA 
 
 Consumables 4.1.3
1.5 ml tube Eppendorf, Hamburg, Germany 
10 ml syringe discardit II BD Medical, Franklin Lakes, USA 
2.5 ml tube Eppendorf, Hamburg, Germany 
20G venous catheter Introcan B.Braun, Melsungen, Germany 
20G/27G BD microlance 3 BD Medical, Franklin Lakes, USA 
5 ml polystyrene round bottom tubes  BD Biosciences, San Jose, USA 
50 ml /15 ml tubes BD Biosciences, San Jose, USA 
Cell strainer 40/70/100µm BD Biosciences, San Jose, USA 
Cover glasses 24x60 mm Menzel, Braunschweig, Germany 
Embedding cassetes Rotilabo ROTH, Karlsruhe, Germany 
Micro Slides Hecht- Assistant, Sondheim, Germany 
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Pipette tips (10/20/100/1000 µl) Eppendorf, Hamburg, Germany 
 
 Reagents 4.1.4
7- Aminoactinomycin Sigma-Aldrich, Saint-Louis, USA 
Acetic acid 100% ROTH, Karlsruhe, Germany 
BD PharmLyse BD Biosciences, San Jose, USA 
Bleomycin Sigma-Aldrich, Saint-Louis, USA 
Collagenase A Roche Applied Science, Mannheim, Germany 
DNase I AppliChem, Darmstadt, Germany 
EDTA 0.5M  Life Technologies, Darmstadt, Germany 
FCS GE Healthcare, Buckinghamshire, UK  
Formaldehyd 4% Pharmacy LMU Munich, Germany 
NaCl 0.9 % B.Braun, Melsungen, Germany 
Paraffin Thermo scientific, Walldorf, Germany 
PBS Life Technologies, Darmstadt, Germany 
RPMI 1640 Glutamine - Life Technologies, Darmstadt, Germany 
Trypan blue Sigma-Aldrich, Saint-Louis, USA 
 Narcotics and Antidote 4.1.5
Atipamezol (Antisedan) Pfizer, New York, USA 
Fentanyl-Janssen 0.5 mg Janssen-Cilag, Neuss, Germany 
Flumazenil (Anexate) Roche, Basel, Swizerland 
Ketamin 10 % Medistar, Ascheberg, Germany 
Medetomidin (Dormitor) 1mg/ml Pfizer, New York, USA 
Midazolam –HCL 15mg/3ml Ratiopharm, Ulm, Germany 
Naloxon 0.4mg/ml Inresa, Freiburg, Germany 
Xylazin 2% (Rompun) Bayer Health Care, Leverkusen, Germany 
 
 Antibodies 4.1.6
Anti-mouse CCR10 PE R&D Systems, Minneapolis, USA 
Anti-mouse CCR3 PE R&D Systems, Minneapolis, USA 
Anti-mouse CXCR4 PE R&D Systems, Minneapolis, USA 
Anti-mouse CXCR5 PE R&D Systems, Minneapolis, USA 
Anti-mouse CXCR6 PE R&D Systems, Minneapolis, USA 
APC H7 rat IgG2b, κ isotype control BD Biosciences, San Jose, USA 
APC-H7 rat anti mouse CD4 BD Biosciences, San Jose, USA 
FITC anti-mouse CD8b Biolegend, San Diego, USA 
FITC anti-mouse/human CD44 Biolegend, San Diego, USA 
FITC rat IgG2b, κ isotype control Biolegend, San Diego, USA 
Monoclonal anti-mouse CCR2 APC R&D Systems, Minneapolis, USA 
Pacific Blue anti-mouse CD3 Biolegend, San Diego, USA 
Pacific Blue Rat IgG2b, κ Biolegend, San Diego, USA 
PE anti-mouse CD 194 (CCR4) Biolegend, San Diego, USA 
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PE anti-mouse CD 195 (CCR5) Biolegend, San Diego, USA 
PE anti-mouse CD 196 (CCR6) Biolegend, San Diego, USA 
PE anti-mouse CD183 (CXCR3) Biolegend, San Diego, USA 
PE anti-mouse CD62L Biolegend, San Diego, USA 
PE Armenian Hamster IgG isotype contol Biolegend, San Diego, USA 
PE Rat IgG2a, κ Biolegend, San Diego, USA 
PE-anti-mouse CD 197 (CCR7) Biolegend, San Diego, USA 
PE-anti-mouse CD 199 (CCR9) Biolegend, San Diego, USA 
Rat IgG2a isotype control PE R&D Systems, Minneapolis, USA 
Rat IgG2b isotype control APC R&D Systems, Minneapolis, USA 
Rat IgG2b isotype control PE R&D Systems, Minneapolis, USA 
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 Methods 4.2
 Mice 4.2.1
For all experiments, 8 to 11 week old C57BL/6 mice were used. Mice were housed in the 
animal facility of the Institute of Lung Biology and Disease, Helmholtz Zentrum Munich, 
Neuherberg. Cages were implemented with 2 to 4 mice; standard food and water were 
available ad libitum. The experiments were approved by the District Government of Upper 
Bavaria. 
 Induction of pulmonary fibrosis 4.2.2
 Preparation of Reagents 4.2.2.1
For anaesthesia during the treatment procedure, a mixture of Midazolam, Medetomidin and 
Fentanyl (MMF) was used because all of the components can be antagonized. In this way the 
anaesthetization time could be held short.  
The stock solution was prepared using 1ml Midazolam (5mg/ml), 0.5 ml Medetomidin 
(1mg/ml), 1ml Fentanyl (50µg/ml).  
Antidote was prepared using 3 ml Naloxon (0.4mg/ml), 0.5ml Atipamezol (5mg/ml), 5ml 
Flumazenil (0.5mg/5ml). Bleomycin was prepared as stock solution of 3U/ml in sterile NaCl 
0.9% and stored at -20°C in aliquots of 350µl. 
For one mouse of 20g 33.4 µl of stock solution was diluted with 166 µl sterile NaCl 0.9%, 
resulting in 0,1 U in 200 µl solution (0.5U/ml) correspondent to 5U/kg body weight. 
 Treatment procedure 4.2.2.2
Body weight was recorded before mice were anesthetized by intraperitoneal injection of the 
MMF mixture according to their body weight. For example, a mouse of 20g received 50µl. 
After confirmation of anaesthesia by checking the reaction to pain, mice underwent 
intratracheal intubation using a 21G venous catheter. Correct intubation was controlled by 
observation of thoracic excursions during mechanical ventilation. 200µl sterile NaCl 0.9% or 
200µl of the prepared Bleomycin solution were instilled as aerosol, using a pneumatic 
pressure device for controlled application of pressure on the high pressure syringe. 
Anaesthesia was antagonized by subcutaneous injection of Naloxon, Atipamezol, Flumazenil 
solution, according to the body weight (for example 170µl for a mouse of 20 g). 
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 Sampling of lung, spleen and BALF 4.2.3
 Preparation of reagents 4.2.3.1
Because it was not necessary to antagonize the anaesthesia, a mixture of Ketamin and 
Xylazin was used to anaesthetize mice for the organ removal. The stock solution was 
prepared by adding 1ml of Ketamin 10% and 0.25ml of Xylazin 10% to 6ml PBS. 
Collagenase was prepared as stock solution of 5mg/ml. For 20 ml of stock solution 100 mg of 
CollagenaseA lyophilizate were dissolved in 20 ml PBS and the solution was stored at 4°C. 
For preparation of DNAse stock solution 10ml of 0.15M NaCl solution were prepared by 
dissolving 87.66mg of NaCl in 10 ml aqua dest, 10mg of lyophilized DNAse was dissolved in 
the prepared NaCl solution, resulting in a concentration of 1mg/ml. The stock solution was 
stored in aliquots at -20°C. 
For lung digestion, 3.8 ml of RPMI 1640 medium were transferred to a 50 ml tube. Then, 
700µl of CollagenaseA stock solution (0.7mg/ml) and 500µl of DNAse (0.1mg/ml) stock 
solution were added. 
For digestion of spleens, 4.6 ml of RPMI 1640 medium were transferred to a 50ml tube and 
234µl of CollagenaseA stock solution and 167µl of DNAse stock solution was added, resulting 
in 5 ml medium with a concentration of 0.234 mg/ml collagenase and 33.4 µg/ml DNAse. 
 Organ removal 4.2.3.2
To detect body weight changes at the different time points after bleomycin treatment, the 
body weight was recorded again. Then, the Ketamin/Xylazin mixture was injected ip 
according to the body weight, for a mouse of 20g this were 200µl. Deep anaesthesia was 
confirmed by checking the reaction to pain. The abdomen was opened, and then the spleen 
was removed and transferred to a petri dish containing 5 ml digestion medium. The spleen 
was dissected with forceps and the cell suspension was transferred to a 50ml tube. 
Mice were sacrificed by exsanguination through cutting the abdominal aorta. For collection 
of bronchio-alveolar lavage fluid (BALF), the trachea was exposed and a 20G venous catheter 
was placed in the trachea. BAL was performed by instilling and aspirating of 1ml PBS three 
times, using a 1 ml syringe. BALF was stored on ice until further processing. 
To remove the lungs, the chest was opened and the blood in the pulmonary vessels was 
removed from the lung by lung perfusion through injection of 10 ml PBS in the right heart 
ventricle. 
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Lungs were removed and either both lungs were transferred to 5 ml of the digestion 
medium or formalin was instilled in the right lung for histology and the left lung was 
transferred to a petri dish with digestion- medium. The lung tissue was dissected using 
forceps and the plunger of a 1ml syringe. The tissue-medium mixture was transferred to a 
50ml tube. 
 Preparation of cells for FACS 4.2.4
 Preparation of Reagents 4.2.4.1
BD PharmLyse reagent was diluted 1:10 with milliQ water. For preparation of the staining 
buffer 2ml of 0.5M EDTA and 2.5 ml FCS were added to 500ml PBS resulting in 2mM EDTA 
and 0.5% FCS solution. 
 BAL 4.2.4.2
The amount of aspirated BALF was recorded. BALF was centrifuged at 350G for 10 min to 
obtain BAL cells. Cells were resuspended in 200 µl staining medium. 
10µl of the cell suspension were diluted 1:2 with 10µl of Trypan blue/4% acidic acid. Living 
cells were counted using a Neubauer haemocytometer. Four big squares were counted and 
cell number was calculated regarding the size of the haemocytometer: 
 
𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐4 ∗ 104 ∗ 𝑐𝑑𝑐𝑐𝑐𝑑𝑐𝑐 ∗ 𝑣𝑐𝑐𝑐𝑣𝑐(𝑣𝑐) 
 Spleen 4.2.4.3
The cell suspension was incubated at 37°C and 80 RPM for 10 minutes. After incubation, the 
spleen cell suspension was passed through 70µm and 40µm cell strainers, and each was 
washed with 2.5 ml of staining buffer. An aliquot of 10µl was taken out for cell counting. 
The suspension was centrifuged at 200G for 10 min. The supernatant was discarded, and the 
cell pellet was resuspended to a concentration of 107cells/ml. 
For counting, the aliquot was diluted 1:10 with staining buffer. 10 µl of the dilution was 
mixed 1:2 with trypan blue 4% acidic acid, resulting in a final dilution of 1:20. Living cells 
were counted as described above. 
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 Lung 4.2.4.4
Lungs from saline-treated animals were incubated for 30 minutes, lungs from bleomycin 
treated mice were incubated for 40 minutes at 37°C and 80 RPM. After incubation, the 
tissue-medium mixture was passed through a 20G cannula using a 10ml Syringe to get a 
single cell suspension. The suspension was then passed through a 100µm and a 70µm cell 
strainer, and each was washed with 2.5ml staining medium. An aliquot of 40µl was taken for 
cell counting. For this, 10µl of the aliquot were diluted 1:2 with trypan blue 4% acidic acid. 
The cell suspension was centrifuged at 200G for 10 min. The supernatant was discarded and 
the pellet was resuspended to a concentration of 107cells/ml. 
 Experimental settings 4.2.5
 Compensating for spectral overlap of fluorochromes 4.2.5.1
For multi-colour FACS experiments, a compensation for the overlap of emission spectra of 
different fluorochromes is necessary. The principle of this compensation is the subtraction of 
the so-called “spilled over” signal (Figure 2). 
 
Figure 2 Emission spectra of FITC and PE with respective filter bandpass; illustration adapted from (69) A) 
contigency of FITC signal which is detected in the FITC channel (green); B) contigency of FITC signal “spilling 
over” into the PE channel (orange), which has to be subtracted from the detected PE signal; C) only a very small 
portion of the PE signal is spilling into the FITC channel; D) contingency of PE signal which is detected in the PE 
channel 
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To assess this signal spill-over, it is necessary to use one unstained sample and samples that 
are each stained with one single fluorochrome. 
Different cell types in spleen and lung result in different background fluorescence. 
Therefore, the compensation for spectral overlap was set up separately for the different 
organs. 
Cells were prepared as described above. 50µl of cell suspension (0.5 x106 cells) were 
transferred to 5 ml round bottom tubes and antibodies were added (Table 1). 
Table 1 Antibodies and set-up used to compensate for spectral overlap of fluorochromes 
 CD3-PB 
(1:10) 
CD4 APC-H7 CD8-PE 
(1:10) 
CD8-FITC 
(1:10) 
CD45-APC 7-AAD 
1       
2 2.5 µl      
3  0.625 µl     
4   3.125 µl    
5    3.125 µl   
6     0.625 µl  
7      3 µl 
 
After staining, cells were incubated for 20 min at 4° C. Contaminating erythrocytes were 
lysed by adding 2 ml of BD PharmLyse followed by 5 min incubation at room temperature. 
The lysis reagent was removed after a centrifugation step at 200G and 5°C, and cells were 
washed with 2 ml staining buffer. After another 5 min of centrifugation the cell pellet was 
suspended in 300 µl staining buffer 
The FACS Diva software provides an automated tool for setting up the compensation. These 
settings were used for all FACS experiments done in this study. 
This automatic compensation setup using FACS Diva software gave the following results for 
spectral overlap of fluorochromes in percent of the recorded signal (Table 2 and Table 3). 
Table 2 Spectral overlap for spleen samples 
Percent FITC PE 7-AAD PB APC APC H7 
FITC 100 1.15 0.05 0.20 0 0.03 
PE 20.57 100 0.64 0 0 0 
7-AAD 2.98 21.08 100 0 1.09 0 
PB 0.02 0 0 100 0 0 
APC 0.06 0.04 4.17 0.47 100 0.88 
APC H7 0.01 0 2.37 0.15 19.37 100 
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Table 3 Spectral overlap for lung samples 
Percent FITC PE 7-AAD PB APC APC H7 
FITC 100 1.16 0 3.42 0.03 0.37 
PE 20.01 100 1.72 2.66 0.01 0.10 
7-AAD 2.58 20.28 100 0.95 1.09 0.12 
PB 0.05 0.01 0 100 0.02 0.07 
APC 0.09 0.04 4.04 2.29 100 1.16 
APC H7 0.02 0 2.27 0 17.82 100 
 
 Longitudinal assessment of T cell percentages after BLM treatment  4.2.5.2
For BAL cells, 200µl of cell suspension were divided in two 5ml round bottom tubes. Cells 
were stained with directly labelled antibodies (Table 4). 
Table 4 Antibodies used for BAL samples 
Antibody (dil) 1 2 
CD3-PB (1:10) 2.5 µl 2.5 µl 
CD4-APC-H7 0.625 µl 0.625µl 
CD8-FITC (1:10) 1.25 µl 1.25 µl 
CCR2-APC 1.25 µl  
Rat IgG2b-APC  1.25 µl 
7-AAD 3 µl 3 µl 
 
For spleen and lung samples, 25µl of the cell suspension (107 cells/ml) were transferred to 
each 5 ml tube resulting in 250 000 cells per tube and the antibodies were added to the 
tubes (Table 5). 
Table 5 Antibodies used for spleen and lung samples 
Antibody (dil.) 1 2 3 4 
CD3-PB (1:10) 2.5 µl 2.5 µl 2.5 µl 2.5 µl 
CD4-APC-H7 0,625 µl 0,625 µl 0,625 µl 0,625 µl 
CD8-FITC (1:10) 1,25 µl 1,25 µl   
CD44-FITC 
(1:10) 
  2,5 µl 2,5 µl 
CD62L-PE (1:10)   3,125 µl 3,125 µl 
CCR2-APC 1,25 µl  1,25 µl  
Rat IgG2b-APC  1,25 µl  1,25 µl 
7AAD 3 µl 3 µl 3 µl 3 µl 
 
Samples were incubated for 20 min at 4°C in the dark. 2 ml 1:10 diluted BDpharmLyse 
reagent was added to each tube for red blood cell lysis, followed by 5 min incubation at 
room temperature in the dark. The lysis reagent was removed by centrifugation at 200g for 5 
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min and an additional washing step with 2 ml staining buffer. The cell pellet was 
resuspended in 300 µl staining buffer. Samples were analysed on a BD LSRII Flow cytometer. 
 Assessment of CCR/CXCR co-expression on lung T cells 4.2.5.3
Due to the paucity of pulmonary CCR2+ T cells, it was not possible to co-stain all chemokine 
receptors of interest in one single experiment. Therefore, the experiment was subdivided 
into three staining panels. Each, one mouse was used per panel with a total of 6 to 7 mice 
per panel. 
For the assessment of the cytokine receptor co-expression, cells were also resuspended to a 
concentration of 107 cells/ml. 100 to 200µl of cell suspension, depending on counted cell 
numbers, were transferred to each 5 ml tube. Antibodies were added to the tube (Table 6). 
Incubation, red blood cell lysis and washing steps were performed as described above in 
section 4.2.5.2. 
Table 6 Antibodies used for assessment of chemokine receptor expression 
Amount for 106 
cells 
        
All tubes 1 2 3 4 5 6 7 8 
CD3-PB 1 µl 1 µl 1 µl 1 µl 1 µl 1 µl 1 µl  
CD4-APC H7 2.5 µl 2.5 µl 2.5 µl 2.5 µl 2.5 µl 2.5 µl 2.5 µl  
CD8-FITC 0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl  
7-AAD 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl  
         
Panel 1 1 2 3 4 5 6 7  
CCR2-APC 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl   
Rat IgG2b-APC       5 µl  
CCR4-PE  5 µl       
CCR5-PE   2.5 µl      
CCR6-PE    5 µl     
CXCR3-PE     1.25 µl    
AH-IgG-PE      5 µl 5 µl  
         
Panel 2 1 2 3 4 5 6 7 8 
CCR2-APC 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl   
Rat IgG 2b-APC       5 µl 5 µl 
CXCR5 5 µl        
CCR3  5 µl       
Rat IgG2a-PE   5 µl    5 µl  
CCR7    10 µl     
CCR9     5 µl    
Rat IgG2a, κ-PE      10 µl  10 µl 
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Panel 3 1 2 3 4 5    
CCR2-APC 5 µl 5 µl 5 µl 5 µl     
Rat IgG2b-APC     5 µl    
CCR10 5 µl        
CXCR4  5 µl       
CXCR6   5 µl      
Rat IgG2b-PE    5 µl 5 µl    
 Data Analysis 4.2.6
 Analysis of FACS data 4.2.6.1
For analysis of FACS data BD FACS Diva Software was used. 
 
 
Figure 3 First step in the analysis of FACS data; example of a lung sample; a) dot plot of all measured events; 
b)dot plot of all measured events gate is drawn for separation of single cells and excludes particles of small size; 
c) dot plot of single cells, gate is selecting living cells 
 
Cells adhering together can alter the result of FACS experiments, since they can mimic a cell 
population which does not exist. For example CD4+ cells adhering to CD8+ cells may mimic a 
population of CD4+CD8+ cells, because in this case, the detectors for both fluorochromes 
bound to the different antibodies detect a signal. 
These adhering cells can be excluded using a dot plot showing the area scaled FSC (FSC-A) 
versus the height scaled FSC (FSC-H). Adhering cells appear below the diagonal because the 
ratio of the height of the FSC signal compared to the area is lower (Figure 3b). 
To exclude these biases, only events appearing near the diagonal were taken into the 
analysis and were selected in the first electronic gate. For the next step, these single cells 
were shown in a dot plot with FSC-A versus the fluorescence of 7AAD. The gate for living 
cells was drawn for cells negative for 7AAD fluorescence and considering FSC-A signal to 
exclude death cells and also cell trash which give high background fluorescence (Figure 3c). 
This procedure was followed for all samples. 
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4.2.6.1.1 Longitudinal assessment of T cell percentages after BLM treatment 
For the identification of T lymphocytes, living cells were shown in a histogram and CD3+ cells 
were selected according to the intensity of the PB signal (Figure 4). 
 
 
For spleen and lung samples, histograms showing only CD3+ cells were drawn. CD4+ cells 
were selected in an electronic gate according to the APC-H7 signal, CD8+ cells according to 
the FITC fluorescence (Figure 5). 
 
 
 
BAL samples contain many cells emitting background fluorescence in all channels. For this 
reason, it was not possible to exclude these cells with the CD3 gate. To be able to exclude 
Figure 4 Histogram showing living cells; x-
axis showing PB fluorescence intensity; gate 
selecting CD3+ cells 
a b 
Figure 5 Histograms showing CD3+ cells a) APC-H7 fluorescence intensity on the x-
axis; gate selecting CD4+ cells; b) FITC fluorescence intensity on the x-axis; gate 
selecting CD8+ cells; the CD8low population presumably represents NK cells 
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this population which gave a signal in both, the FITC and the APC-Cy7 channel, for BAL 
samples, CD3+ cells were shown in a dot plot with FITC intensity for CD8+ T cells versus APC-
H7 intensity for CD4+ T cells. Events only positive for APC-H7 fluorescence were selected as 
CD4+ T cells. Events only positive for FITC fluorescence were selected as CD8+ T cells (Figure 
6). 
 
 
For the assessment of percentages of CCR2+ T cells, histograms showing only CD4+ or CD8+ 
cells were used. The percentage of CCR2 expressing cells was determined according to the 
APC signal intensity. For this, the sample stained with the specific antibody was compared to 
a sample stained with the appropriate isotype control (Figure 7). 
 
 
 
Figure 6: BAL sample; Dot plot showing 
CD3+ cells, gates selecting CD4+ or CD8+ 
cells 
a b 
Figure 7 Histograms showing CD4+ cells; APC fluorescence intensity on the x-axis, 
a) sample stained with antibody binding to CCR2, b) sample stained with an 
appropriate isotype control 
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For spleen and lung samples, CD4+ T cell subtypes were analysed additionally. CD3+, CD4+ T 
cells, and CCR2 expressing CD4+ T cells were selected as described above. 
Naïve, central memory, and effector memory T cells were detected through the expression 
of CD44 and CD62L. CD4+ cells were shown in a dot plot drawing CD44-FITC signal versus 
CD62L-PE fluorescence intensity. CD44lowCD62Lhigh expressing cells were considered as naïve 
cells (Tnaive). CD44highCD62Lhigh cells were considered as central memory cells (Tcm) and 
CD44highCD62Llow cells as effector memory cells (Tem) (Figure 8).  
 
 
The percentage of CCR2+ cells within CD4 T cell subpopulations was assessed using 
histograms showing naïve, central memory or effector memory CD4 T cells. The percentages 
of CCR2+ cells were determined by comparison of samples stained with the specific antibody 
to samples stained with an appropriate isotype control (Figure 9). 
Figure 8 Dot plot showing CD4+ T cells, quadrants determining CD4+ T cell subtypes, upper left 
quadrant: naïve T cells, upper right quadrant central memory T cells, lower right quadrant effector 
memory T cells 
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4.2.6.1.2 Assessment of chemokine receptor co-expression 
To be able to identify the CD3+ population more clearly, an additional lymphocyte gate was 
introduced. Living cells were shown in a dot plot showing FSC-A versus SSC-A. The 
lymphocyte gate was drawn based on the granularity (SSC) and the size (FSC) of the 
lymphocyte population (Figure 10). 
 
a b c 
d e f 
Figure 9 Histograms showing T-cell subtypes, in lung samples; upper row showing a sample stained with an 
antibody specific for CCR2; lower row showing a sample stained with an approproate isotype control; a+d ) naïve 
CD4+ T cells; b+e) central memory CD4 T cells; central memory T cells were too rare to be assessed adequately; c+f) 
effector memory cells 
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This selected population was then transferred in a histogram to select of CD3+ cells- CD4+, 
CD8+ and CCR2+ populations were selected using electronic gates as described above (Figure 
4, Figure 5 and Figure 7) 
The next step was to determine the expression of the other chemokine receptors on CD4+ 
and CD8+ T cells. For this, the same strategy was used as for the assessment of CCR2 
expression, but using PE as fluorocrome. 
CCR2 (APC) was plotted against other chemokine receptors (PE) within CD4+ or CD8+ T cells. 
To calculate percentages of cells expressing CCR2 as well as the other chemokine receptor, 
the tube stained with both specific antibodies was compared to two isotype samples (Figure 
11). 
 
Figure 11 Example for assessment of chemokine receptor co-expression with CCR2, Dot plots show CD4+ cells 
stained with a) both chemokine receptor-specific antibodies b) the isotype control for CXCR6-PE and the 
antibody specific for CCR2 c) both isotype controls 
 
Figure 10 Dot plot showing living cells; 
gate selecting lymphocytes  
a b c 
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As basis for the statistical analysis, the percentages of cell populations given by the statistic 
view of FACS Diva software were used. Percentages of CD4+ and CD8+ T cells were calculated 
back to living cells. For parameters detected more than once for one animal, means were 
calculated and taken into the analysis. 
 Statistical Analysis 4.2.6.2
Due to the low number of samples in most of the experimental groups, a normal distribution 
could not be assumed. Therefore, nonparametric tests were used for statistical analysis. For 
comparison of body weight before and after treatment, Wilcoxon signed rank test was used. 
For comparison of two unpaired groups, nonparametric Mann Whitney U test was 
performed. Comparisons of the groups in the longitudinal experiments were done using 
Kruskal Wallis test followed Dunn’s multiple comparison test. By this test, treatment groups 
at the different time points were compared to the control group. For all calculations, 
GraphPad Prism software was used. Significance was accepted for p < 0.05. 
 Histology 4.2.7
For histology, the right lung was cut from the whole lung and 4%formalin was instilled in the 
main bronchus for fixation. The lung was put into a 50 ml tube containing 4% formaldehyde 
solution and incubated overnight. 
The next day, the lung was cut into superior, middle, inferior, and postcaval lobe. The four 
lobes were arranged in an imbedding cassette, paraffinated overnight, and imbedded in a 
parrafine block. Blocks were cut to 3 µm slices and transferred to a glass slide. For 
deparaffination, the slides were washed for 5 minutes in xylol, and then they were washed 
two times for one minute in 100% ethanol and one minute in each, 90%, 80% and 70% 
ethanol. 
 Haematoxylin Eosin (HE) staining 4.2.7.1
Slides were rinsed shortly with Aqua dest and then stained for 5 minutes with Mayer’s 
Hämatoxylin. They were rinsed shortly with water and 0.3% HCl-alcohol followed by 10 to 15 
minutes washing in tap water. After rinsing again with Aqua dest; slides were stained with 
Eosin Y for 8 minutes. For dehydration, the samples were washed shortly in 70% and 80% 
ethanol, followed by washing steps in 90%, 96% and 100% ethanol for one minute, each. 
Finally they were washed for two minutes in 100% ethanol and two times for 5 minutes in 
Xylol. Slides were covered with cover glasses using entellan. 
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 Masson Goldner’s Trichrom staining 4.2.7.2
For Masson Goldner’s Trichrom staining, slides were stained with Weigert’s Hämatoxylin for 
10 minutes, followed by washing for 3 min in tap water. After 1 min incubation in 0.3% HCl-
alcohol, slides were washed again for 3 minutes in tap water. Slides were rinsed shortly with 
Aqua dest before staining in ponceau fuchsin acid for 6 minutes. They were rinsed shortly 
with Aqua dest, 1% acetic acid, and again with Aqua dest followed by 5 minutes incubation 
in phosphormolybdic acid-orange g. Slides were rinsed again shortly with 1% acetic acid and 
stained with light green 0.2%. The staining was finished by rinsing again with 1% acetic acid 
and aqua dest. Dehydration was performed as described for HE staining. 
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 Experimental outline 5.1
The overall aim of this project was to characterize the phenotype of CCR2+ T cells in the 
context of experimental interstitial lung disease. For this, a widely common model for 
pulmonary fibrosis based on the intratracheal administration of Bleomycin was used. The 
experimental outline for the longitudinal analysis is shown in Figure 12. 
 
Figure 12 Experimental outline of bleomycin induced Lung fibrosis; 200µl of bleomycin solution or 0.9% NaCl 
was instilled intratracheally; mice were sacrificed at the indicated time points. Spleen, BAL and lung were taken 
for analysis at each time point. 
 
The first goal was to investigate changes of the composition of T cells and T cell subtypes in 
spleen, lung, and BALF during the longitudinal development of fibrosis. Furthermore, we 
wanted to determine the time point with maximal pulmonary CCR2+ T cell content in order 
to set the optimal time point for further examination of this population. 
In a second step, the percentages of CCR2+ CD4+ and CD8+ T cells also expressing other 
chemokine receptors were investigated at the time point chosen from the results of the 
different time points. 
 Characterization of the animals 5.2
 Animal numbers 5.2.1
Table 7 gives an overview of sampled tissues at the different time points. From day 12 on an 
increasing death rate of 11% at day 12 to 61% at day 21 was observed in the group of BLM 
treated animals. 
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Table 7 Number of animals for time course experiments 
 Saline Day 3 Day 6 Day 9 Day 
12 
Day 
15 
Day 
18 
Day 
21 
Treated animals 14 10 17 15 18 14 19 18 
BALF only 4 3 5 5 5 1   
BALF & lung      2 4 2 
Lung & BALF& spleen 3 2 3 2 3 1 1 3 
Lung & spleen 7 2 9 8 8 4 5 2 
Lung only  3       
excluded      1 1  
died     2 5 8 11 
Final animal numbers analysed 
BALF 7 5 8 7 8 4 4 5 
Lung 10 7 12 10 11 7 6 7 
spleen 10 4 12 10 11 5 6 5 
Body weight# 12 10 13 15 13 9 11 7 
#Body weight was not detected in the first run of time course: 2 saline treated animals, 4 BLM treated day 6 
and 3 BLM treated Day 12. 
 Change of body weight 5.2.2
The body weight change was assessed as indicator of disease severity. Most mice lost body 
weight following BLM treatment (Table 10). 
Table 8 Body weight on D0 and the different time points 
  BW D0 (g)* BW D 3 to 21 (g) p-value# 
Sal  n = 12 20.2 (19.0-23.0) 20.8 (18.7-23.2) 0.15 
Day 3  n = 10 19.7 (18.6-21.1) 19.1 (18.0-19.8) 0.002 
Day 6  n = 13 19.8 (18.9-22.0) 17.9 (13.2-23.3) 0.004 
Day 9  n = 15 20.0 (17.8-21.5) 18.0 (13.1-20.2) 0.0003 
Day 12  n = 13 19.0 (17.9- 22.3) 19.0 (13.5-21.0) 0.3 
Day 15 n = 9 19.4 (18.0-21.0) 17.5 (12.7-19.8) 0.04 
Day 18 n = 11 19.9 (17.5-21.0) 19.1 (13.3-22.1) 0.19 
Day 21 n = 7 18.7 (18.0-19.9) 17.5 (13.0-21.6) 0.3 
* Values are expressed as median (range) 
# p-values indicate significance of body weight difference at different time point vs. day 0 by Wilcoxon paired 
rank test. 
 
At days 3, 6, 9, and 15, mice showed a significant loss of body weight compared to the body 
weight measured at day 0. At the other time points, the body weight change was more 
inhomogeneous with some mice extensively loosing body weight (up to 8.8 g) and others 
keeping their weight or even gaining body weight. The body weight in the control group was 
stable (Table 8). 
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When the body weight change was compared between the different time points after 
bleomycin treatment and the control group, a significant loss of body weight was found at 
days 6, 9, and 15 (Figure 13). 
 
Figure 13 Body weight change over time course; indicated p-values obtained by Dunn Multiple Comparison 
test; Kruskal Wallis test: **p<0.01 
 Histology 5.2.3
Histology sections were done to assess the distribution and severity of fibrotic lesions in the 
lungs of BLM treated mice. 
Figure 14 shows Goldner’s masson tricrome staining of histological sections from right lungs 
at the time points examined after BLM treatment. The pictures show representative areas 
affected from lung injury at the indicated time points. All sections also contained areas of 
histologically unaffected tissue to a variable extend. In sections from saline treated mice 
there were no inflammatory or fibrotic lesions. At days 3 and 6, the accumulation of 
inflammatory cells dominated over fibrotic lesions reflecting the initial inflammatory phase 
of BLM induced fibrosis. From day 9, thickening of alveolar walls and markedly enhanced 
collagen deposition were the leading features. The distribution of the lesions was mainly 
peri-bronchial, although in some sections also sub-pleural alterations were observed. 
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Figure 14 Masson Goldner’s Tricrom stain of histological sections of lung tissue from saline or BLM treated 
mice 
Day 3 Sal 
Day 6 Day 9 
Day 12 Day 15 
Day 18 Day 21 
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 Longitudinal assessment of T cells 5.3
 Spleen 5.3.1
 Percentages of CD4+ and CD8+ T cells 5.3.1.1
To investigate if BLM treatment evokes a systemic T cell response, spleen cells were 
analysed. The relative content of CD4+and CD8+ T cells within the spleen cell populations did 
not change significantly at the time points examined (Table 9). Thus there was no hint for a 
systemic reaction of the T cells at the quantitative level. 
Table 9 Percentages of CD4+ and CD8+ T cells within total living cell population in spleen samples 
  CD4* CD8 
Sal n = 10 22.3 (18.2-25.4) 15.7 (7.4-20.0) 
Day 3 n = 4 20.5 (18.2-23.4) 10.22 (9.0-15.1) 
Day 6 n = 12 23.9 (18.8-27.7) 15.7 (12.1-28.8) 
Day 9 n = 10 21.7 (17.5-27.6) 14.1 (11.0-21.5) 
Day 12 n = 11 19.5 (15.0-28.1) 15.7 (9.8-22.5) 
Day 15 n = 5 21.3 (21.1-21.7) 17.7 (11.9-23.9) 
Day 18 n = 6 22.8 (18.5-30.9) 17.7 (13.3-22.1) 
Day 21 n = 5 19.9 (17.6-26.6) 13.3 (9.5-18.7) 
* Values are expressed as median (range) 
 Naïve, central memory and effector memory CD4+ T cells 5.3.1.2
To asses also changes in the spleen T cell activation status, T cell memory subtypes were 
analysed. Naïve T cells were the main CD4+ T cell population with about 80%, followed by 
effector memory CD4+ T cells (about 10%). Among the different time points, there was no 
change in the relation of the different subsets (Table 10). 
Table 10 Percentages of CD4+ T-cell subtypes within total CD4+ T cells in spleen  
  Naïve*  CM EM 
Sal n = 10 81.3 (71.4-83.1) 3.2 (2.2-4.8) 9.9 (9.0-16.2) 
Day 3 n = 4 80.2 (79.6-81.1) 2.4 (2.1-3.1) 8.9 (7.2-9.8) 
Day 6 n = 12 78.9 (74.2-83.6) 3.5 (1.5-5.1) 10.6 (7.9-15.6) 
Day 9 n = 10 80.4 (68.0-86.7) 3.1 (2.2-4.9) 9.2 (6.9-17.6) 
Day 12 n = 11 79.0 (57.1-83.4) 3.4 (1.8-5.9) 11.7 (8.8-20.7) 
Day 15 n = 5 84.8 (80.8-85.9) 2.3 (1.1-3.0) 8.7 (6.8-10.7) 
Day 18 n = 6 83.7 (78.9-87.9) 2.3 (1.6-4.0) 8.6 (6.3-12.6) 
Day 21 n = 5 77.3 (76.8-84.0) 3.0 (2.0-4.3) 12.2 (9.1-14-2) 
* Values are expressed as median (range) 
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 CCR2 expression 5.3.1.3
CCR2 was only expressed on a small population of spleen T cells. The relative content of 
CCR2+ cells was nearly similar within CD4+ and CD8+ T cells, and did not differ significantly 
among different time points (Table 11). 
Table 11 Percentages of CCR2 expressing CD4+ or CD8+ cells within total CD4+ and CD8+ cells in spleen 
  CCR2 to CD4* CCR2 to CD8 
Sal n = 10 2.1 (1.1-5.8) 1.2 (0.0-5.5) 
Day 3 n = 4 2.1 (0.94-2.3) 1.5 (0.82-2.5) 
Day 6 n = 12 3.2 (2.1-4.1) 1.8 (0.78-3.6) 
Day 9 n = 10 1.7 (0.74-3.9) 1.2 (0.0-3.3) 
Day 12 n = 11 4.1 (0.0-5.0) 2.2 (0.0-4.3) 
Day 15 n = 5 1.8 (1.6-2.5) 1.9 (1.2-3.8) 
Day 18 n = 6 1.1 (0.1-2.9) 0.88 (0.0-3.3) 
Day 21 n = 5 2.4 (1.4-5.5) 1.1 (0.0-2.2) 
* Values are expressed as median (range) 
 
Table 12 shows percentages of naïve, central memory and effector memory CD4+ T cells 
expressing CCR2. CCR2 was predominantly expressed on Tem cells. Within naïve T cells only a 
small population expressed CCR2. Among the time points, there was no significant difference 
in the percentage of CCR2+ cells within the different subsets. 
Table 12 Percentages of CCR2 expression within CD4+ T-cell subtypes in spleen 
  Naïve  CM EM 
Sal n = 10 0.46 (0.00-6.7) 4.3 (0.00-21) 11 (7.6-20) 
Day 3 n = 4 1.0 (0.65-1.4) 4.6 (0.00-7.5) 16 (14-21) 
Day 6 n = 12 1.0 (0.00-2.2) 5.7 (0.00-33) 19 (7.9-29) 
Day 9 n = 10 0.85 (0.00-1.7) 5.9 (2.2-8.1) 15 (7.5-2) 
Day 12 n = 11 0.08 (0.00-2.0) 5.9 (2.5-18) 12 (7.5-36) 
Day 15 n = 5 0.53 (0.00-1.6) 5.2 (4.4-17) 12 (10-20) 
Day 18 n = 6 0.00 (0.00-0.35) 7.9 (0.00-13) 8.0 (5.0-27) 
Day 21 n = 5 0.58 (0.17-1.2) 8.2 (2.4-25) 11 (9.1-48) 
* Values are expressed as median (range) 
 
In total, no significant changes in T cell content and the distribution of CD4+ T cell subtypes 
have been detected during the longitudinal observation. Thus, there was no hint for a 
systemic T cell response following intra tracheal BLM application. To investigate the local 
effects of BLM treatment, BALF and lung tissue were analyzed in an analogous way. 
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 BALF 5.3.2
  Cell count 5.3.2.1
 
Figure 15 Cell count of BAL during time course; 1ml of sterile PBS was instilled, cell count is given as 104/ml; 
indicated p-values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: ***p<0.001 
 
BAL cells were analyzed to monitor the recruitment of inflammatory cells to the airways of 
BLM treated mice. BAL from untreated mice contains only few cells, which are 
predominantly alveolar macrophages, and nearly no lymphocytes. After BLM treatment, 
median cell counts increased up to 14 times at day 21 compared to saline treated mice. The 
most significant increase was detected at days 12 and 15. However, there was a wide range 
from 41.3 104/ml to 166.5 104/ml at day 12 and 34.5 104 to 150.0 104 at day 15. Notably, two 
animals showed high BAL cell counts, one at day 12 and the other one at day 21. The outlier 
at day 12 corresponds to an extreme loss of body weight of the respective animal, whereas 
the outlier at day 18 did not show an extreme loss of body weight or any other outstanding 
value within the parameters measured. 
 CD4+ and CD8+ T cells 5.3.2.2
As expected, there were nearly no lymphocytes detectable in control mice. The relative 
content of CD4+ T cells was between 0 and 5 %, the relative content of CD8+ T cells between 
0 and 0.3 %. 
In contrast, a significant increase of the percentage of CD4+ T cells compared to the control 
group was found at days 9, 12, 15 and 21. The highest median percentage of CD4+ T cells was 
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detected at day 15. However, there was a wide range, and due to the low number of 
samples analyzed in this group, the result is difficult to evaluate (Figure 16). 
Percentages of CD8+ T cells were increased similar to CD4+ T cells. At the time points from 
day 6 to day 12, the percentage of CD8+ T cells within living cells was significantly higher than 
in the control group (Figure 17). 
An analysis of T cell subtypes in BAL was not possible due to the limited cell number in these 
samples. 
 
Figure 16 Percentages of CD4+ T cells within living BAL cells; indicated p-values obtained by Dunn Multiple 
Comparison test; Kruskal Wallis test: **p<0.01 
 
 
Figure 17 Percentages of CD8+ T-cells within living BAL cells; indicated p-values obtained by Dunn Multiple 
Comparison test; Kruskal Wallis test: **p<0.01 
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 Lung 5.3.3
 CD4+ and CD8+ T cells 5.3.3.1
To further characterize the lymphocyte response to BLM induced lung injury, flow 
cytometric analysis of CD4+ and CD8+ T cells as well as CD4+ T cell subtypes was performed in 
lung tissue. 
Overall, there was a clear increase of the percentage of CD4+ T cells over time. A significant 
difference from control mice, which showed a median percentage of CD4+ T cells of 11% 
(8.7-16%), was detected at day 18 with a median 16% CD4+ T cells (11-22%). Results of all 
time points are shown in Figure 18. 
 
Figure 18 Percentages of CD4+ T cells within total living cells in lung samples during time course; indicated p-
values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: **p<0.01 
 
The longitudinal changes of the percentage of CD8+ T cells differed from the changes of the 
CD4+ T cell population (Figure 19). From day 9 to day 15, the percentage of CD8+ T cells 
decreased significantly compared to the control group (median 7.4%; range 5.2-10%). At day 
18 and day 21, it increased again. The minimum was detected at day 15 with a median CD8+ 
population of 3.7% (2.4-5.2%) within living cells. 
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Figure 19 Percentages of CD8+ T cells within living cells in lung samples during time course; indicated p-values 
obtained by Dunn Multiple Comparison test; Kruskal Wallis test: ***p<0.001 
 
 Naïve, central memory, effector memory T cells 5.3.3.2
Naïve, central memory, and effector memory CD4+ T cells in lung tissue were analyzed 
analogous to spleen samples. CD44lowCD62Lhi naïve T cells built the largest group with 75% 
(58- 83%) of CD4+ T cells in saline treated animals. The percentage of naïve CD4+ T cells 
decreased following BLM treatment with a minimum at day 9 and day 12 (medians 52% and 
58%) (Figure 20). 
 
Figure 20 Percentages of Tnaive CD4
+ cells within total CD4+ T cells in lung samples during time course; 
indicated p-values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: **p<0.01 
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CD44hiCD62Lhi central memory T cells were the smallest group of CD4+ T cell subsets. There 
were no changes of the percentage of Tcm. The median portion of Tcm within total CD4+ T 
cells was between 2.8 % at day 12 and 4.2% in the control group (Figure 21). 
 
Figure 21 Percentages of Tcm CD4
+ cells content within total CD4+ T cells in lung samples during time course; 
indicated p-values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: ns p=0.08 
 
Concurrently to the decrease of Tnaive, CD44hiCD62Llow effector memory cells increased. 
Significantly higher values compared to controls, which showed a median fraction of Tem of 
16% (6.9-23%), were found on day 9 with 31% (17-50%) and day 12 with 27% (15-51%) 
(Figure 22). 
 
Figure 22 Percentages of Tem CD4
+ cells within total CD4+ T cells in lung samples during time course; indicated 
p-values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: **p<0.01 
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 Maximal increase of the percentage of CCR2+ T cells after bleomycin treatment 5.4
 BALF 5.4.1
 Percentage of CCR2 expressing BAL lymphocytes 5.4.1.1
BAL samples of control mice did not contain enough lymphocytes to analyze the fraction of 
CCR2 expressing T cells. For this, values were set to zero for the control group, which also 
allowed statistic testing. Although the baseline percentage of CCR2+ T cells could not be 
displayed, the results imply their increase in BAL following BLM treatment with a maximum 
between day 6 and day 12. After day 12 they decreased again (Figure 23). 
 
Figure 23 Percentage of CCR2+CD4+ T cells within total CD4+ T cells in BAL; indicated p-values obtained by Dunn 
Multiple Comparison test; Kruskal Wallis test: ***p<0.001 
 
A similar kinetic of the percentage of CCR2+ cells was found within the CD8+ T cell population 
in BAL. The median amount of CCR2 expressing CD8+ T cells was between 1.8% (0.58%-2.9%) 
at day 15 and 8.5 % (0.00-11%) at day 9 (Figure 24). 
At day 6, one animal showed a very high percentage of CCR2+ cells within CD4+ T cells (51%) 
and CD8+ T cells (22%) in BAL, but did not show any other extreme values within the 
parameters measured. 
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Figure 24 Percentage of CCR2+CD8+ T cells within total CD8+ T cells in BAL; indicated p-values obtained by Dunn 
Multiple Comparison test; Kruskal Wallis test: *p<0.05 
 Lung 5.4.2
 CCR2+cells within total CD4+ and CD8+ T cells 5.4.2.1
The percentage of CCR2 expressing CD4 T cells increased in lungs of treated mice with a 
maximal percentage at days 9 and 12, and then decreased again at day 18 and day 21. In 
control mice, CCR2 was expressed on 2.3% to 9.8% (median 4.2 %) of CD4+ T cells. At day 9, 
the CCR2+ population within total CD4+ T cells peaked with a threefold increase (14.6%; 
range: 5.8-27%) (Figure 25). 
 
Figure 25 Percentages of CCR2+CD4+ T cells within total CD4+ T cells in lung samples; indicated p-values 
obtained by Dunn Multiple Comparison test; Kruskal Wallis test: ***p<0.001 
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Figure 26 shows the CCR2+ CD4 T cell fraction calculated back to the total living cell 
population. CCR2+CD4+ T cells represented 0.54% (0.24% and 0.85%) of total living cells in 
the control group. Calculated like this, the peak increase was detected at day 12, when 
CCR2+CD4+ T cells constituted between 0.66 and 2.1% (median 1.6%). This was in 
consequence of the slightly higher total CD4+ T cell frequency at this time point. 
 
Figure 26 Percentages of CCR2+CD4+ T cells within total living cells; indicated p-values obtained by Dunn 
Multiple Comparison test; Kruskal Wallis test: **p<0.01 
 
Within the CD8+ T cell population CCR2 expressing cells were slightly rarer than within CD4+ 
T cells. The percentage of CCR2 expressing CD8+ T cells showed an increase with a peak at 
day 9 (median 9.1%) followed by a decrease at days 18 and 21 (medians 1.7% and 4.3%) 
(Figure 27). 
Although the relative content of total CD8+ T cells decreased in lung tissue following BLM 
treatment, CCR2+CD8+ T cells showed a significant increase compared to controls (median 
0.12%) at day 6 (median 0.33%) and day 9 (median 0.28%), when calculated back to total 
living cells (Figure 28). 
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Figure 27 Percentages of CCR2+CD8+ T cells of total CD8+ T cells in lung samples during time course; indicated 
p-values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: ***p<0.001 
 
 
Figure 28 Percentages of CCR2+ CD4+ T cells within total living cells during time course; indicated p-values 
obtained by Dunn Multiple Comparison test; Kruskal Wallis test: ***p<0.001 
 
 CCR2+cells within CD4+ T cell subtypes 5.4.2.2
Like in spleen samples, the portion of CCR2+ cells within the three CD4+ T cell subtypes was 
also analyzed in the lung. Within naïve CD4+ T cells, the frequency of CCR2+ cells was 
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between 0% and 3.7%. It did not vary significantly among different time points following 
BLM treatment and the control group (Figure 29). 
 
Figure 29 Percentages of CCR2+ Tnaïve within total Tnaive during time course; Kruskal Wallis test: ns p=0.08 
 
The CCR2+ central memory population was too small to be analyzed adequately. 
Similar to the result in spleen samples, CCR2 was predominantly expressed on effector 
memory T cells. In control mice, the median percentage of CCR2+ cells within Tem cells was 
23% (14-31%). Following BLM treatment, the percentage was significantly increased at day 
12 (median 34 %, range 20-48%). On the following time points it decreased again (Figure 30). 
 
Figure 30 Percentages of CCR2+ Tem within total Tem during time course, indicated p-values obtained by Dunn 
Multiple Comparison test; Kruskal Wallis test: **p<0.01 
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 Maximal content of CCR2+ T cells 5.4.2.3
To determine the peak of the relative content of CCR2+ T cells, percentages of CCR2+CD4+ T 
cells and CCR2+CD8+ T cells within living cells were added up. With a median percentage of 
2.1%, the frequency of CCR2+ T lymphocytes reached the maximum at day 12. Thus, day 12 
was chosen for the further characterization of CCR2+ T cells. 
 
Figure 31 Sums of the percentages of CCR2+CD4+ and CCR2+CD8+ T cells within total living lung cells; indicated 
p-values obtained by Dunn Multiple Comparison test; Kruskal Wallis test: **p<0.01 
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 Chemokine Receptor Co-expression 5.5
To characterize CCR2+ T lymphocytes in fibrotic lungs, the co-expression of other chemokine 
receptors with CCR2 on T cells was analysed. As mentioned above, CCR2+ T cells were most 
frequent at day 12 after BLM treatment. For that reason, all following experiments were 
performed at this time point. 
 CCR2 5.5.1
The percentage of CCR2+ T cells at day 12 after BLM treatment was analysed again. The 
median percentage of CCR2 expressing cells within CD4+ T cells was 7.9% (4.9-11%) in lungs 
from saline treated mice and 18% (6.4-29%) in samples from BLM treated mice. Thus, CCR2 
expression was slightly higher than on day 12 in the time course experiments. 
The same was seen for CD8+ T cells from control animals, which showed a CCR2 expression 
on 7.4% (3.9-9.2%) of the cells. In samples from BLM treated mice, CCR2+ cells represented 
22% (6.2-34%) of CD8 T cells (Figure 32). 
 
Figure 32 CCR2+ CD4+ and CCR2+CD8+ T cells at day 12 from saline treated control mice and bleomycin treated 
mice; indicated p values obtained by Mann Whitney U test 
 CCR3 5.5.2
In control lungs, CCR3 was expressed on 2.0% (0.00-2.9%) of CD4+ T cells. In BLM treated 
mice, this number was doubled to 4.1% (1.9-5.7%). CCR3+CD8+ T cells were only detected in 
two of 6 samples of control mice (0.9% and 1.3%). In BLM treated animals, CCR3 was 
expressed on 0.9% (0.00-2.5%) pulmonary CD8+ T cells. However, the difference to control 
animals was not significant (Figure 33a). 
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While CCR3+CCR2+CD4+ T cells were almost absent in control mice (median 0.25%), they 
increased to 2% (0.4-3.5%) of CD4+ T cells after BLM treatment. Among CD8+ T cells of 
treated mice, CCR2+CCR3+ cells represented 0.8% of CD8+ T cells (range 0.00-1.7) (Figure 
33b). 
At day 12 after BLM treatment, 11% (2.0-16.2%) of CCR2+CD4+ T cells were CCR3+, 
significantly more than in the saline treated group (4.0%; range 0.0-82%). 
CCR3 was not expressed on pulmonary CCR2+CD8+ T cells from control mice. CCR3 
expression amounted to 3.2% (0.0-6.8%) of CCR2+CD8+ T cells in lungs from BLM treated 
mice (Figure 33c). 
 
Figure 33 CCR3+ T cells at day 12 after BLM treatment a) CCR3+ T cells within total CD4+ or CD8+ T cells; b) 
CCR3+CCR2+ T cells within total CD4+ or CD8+ T cells; c) CCR3+CCR2+ T cells within total CCR2+ CD4+ or CD8+ T 
cells; indicated p values obtained by Mann Whitney U test 
 CCR4 5.5.3
1.2% of CD4+ T cells showed expression of CCR4 under control conditions (range 0.00-3.7%). 
Following BLM treatment, the percentage increased to 3.7% (0.35-8.5%). On CD8+ T cells, the 
percentage of CCR4 expressing cells did not differ among control and treated mice. Only in 
two of the control samples, an expression of CCR4 could be detected (0.6% and 2.4%). In 
BLM samples, CCR4 was expressed on a median percentage of 0.22% (0.00-3.8%) of CD8+ T 
cells (Figure 34a). 
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A co-expression of CCR4 and CCR2 was only found on CD4+ T cells from bleomycin treated 
mice with a median of 0.5% (0.00-3.7%) of CD4+ T cells (Figure 34b). Related to the CCR2+ 
CD4+ T cell population, CCR4+CCR2+ cells amounted to 7.0% (0.00-19%) of CCR2+CD4+ T cells. 
However, statistically the difference between control and BLM group was not significant 
(p=0.052) (Figure 34c). 
 
Figure 34 CCR4+ T cells at day 12 after BLM treatment; a) CCR4+T cells within CD4+ or CD8+ T cells; b) 
CCR4+CCR2+T cells within CD4+ or CD8+ T cells; c) CCR4+CCR2+ T cells within total CCR2+CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
 CCR5 5.5.4
CCR5 was expressed only in single samples on pulmonary CD4+ T cells of saline and 
bleomycin treated animals, as well as on CD8+ T cells from saline treated animals. In 
contrast, 4% (2.5-14.5%) of pulmonary CD8+ T cells from BLM treated mice expressed CCR5 
(Figure 35a). 2.2% (1.3-8.9%) of CD8+ T cells in this group were CCR2+CCR5+ cells (Figure 35b). 
This corresponds to 11% (5.1-34.6%) of CCR5+ cells within CCR2+CD8+ T cells (Figure 35c). 
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Figure 35 CCR5+ T cells at day 12 after BLM treatment; a) CCR5+T cells within CD4+ or CD8+ T cells; b) 
CCR5+CCR2+ T cells within CD4+ or CD8+ T cells; c) CCR5+CCR2+ T cells within total CCR2+ CD4 or CD8 T cells; 
indicated p values obtained by Mann Whitney U test 
 CCR6 5.5.5
CCR6+ cell populations increased significantly after BLM treatment. CCR6 was expressed on 
lung lymphocytes from 3 of 6 control animals on both, CD4+ and CD8+ T cells. The other 
control animals showed no CCR6 expression. In BLM treated mice, CCR6 was expressed on 
13.5% (0.00-23%) of CD4+ T cells and on 11% (0.00-23%) of CD8+ T cells. In one animal no 
CCR6 signal could be detected (Figure 36a). 
Generally, CCR6 was not co-expressed with CCR2 in control mice besides one sample which 
showed 0.9% double positive cells within CD4+ and CD8+ T cells and one sample which 
showed only 0.4% double positive CD8+ T cells. In contrast to the control group, pulmonary T 
cells from BLM treated animals clearly contained a population of CCR2+CCR6+ cells. They 
represented 5.3% (0.0-7.4%) of CD4+ T cells and 4.8% (0.0-10.9%) of CD8+ T cells (Figure 36b). 
Thus, CCR6 was expressed on 34% (0.0-39%) of CCR2+CD4+ cells and on 20% (0.0-45%) of 
CD8+ cells (Figure 36c). 
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Figure 36 CCR6+ T cells at day 12 after BLM treatment; a) CCR6+T cells within CD4+ or CD8+ T cells; b) 
CCR6+CCR2+ T cells within CD4+ or CD8+ T cells; c) CCR6+CCR2+ T cells within total CCR2+CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
 CCR7 5.5.6
CCR7 was the most expressed chemokine receptor on both, CD4+ and CD8+ T cells. 39% (35-
53%) of pulmonary CD4+ T cells and 28% (5.6-36%) of CD8+ T cells from saline treated 
animals expressed CCR7. In the BLM group 43% (30-47%) of CD4+ T cells and 24% (12-37%) of 
CD8+ T cells were CCR7+. Thus, there was no significant difference regarding the frequency of 
CCR7+ cells among the BLM group and controls (Figure 37a). 
CCR2+CCR7+ cells amounted to 3.3% (1.0-5.9%) of CD4+ T cells and 2.4% (0.00-4.8%) of CD8+ 
T cells in control mice. These numbers increased to 5.3% (3.8-13%) of CD4+ T cells and 6.5% 
(3.2-13.2%) of CD8+ T cells in bleomycin treated mice. This significant increase was most 
likely due to the general increase of CCR2 expressing cells (Figure 37b), since the percentage 
of CCR7+ cells within the CCR2+CD4+ and CD8+ T cells did not differ among control and 
treated mice. The relative content of CCR7+ cells in this population was comparable to the 
general percentage of CCR7+ cells within total CD4+ and CD8+ T cells (Figure 37c). Thus, 
CCR2+CCR7+ T cells increased following BLM treatment, but the relation of CCR2+CCR7+ and 
CCR2+CCR7- cells was stable. 
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Figure 37 CCR7+ T cells at day 12 after BLM treatment; a) CCR7+ T cells within CD4+ or CD8+ T cells; b) 
CCR7+CCR2+ T cells within CD4+ or CD8+ T cells; c) CCR7+CCR2+ T cells within  total CCR2+ CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
 CCR9 5.5.7
The expression of CCR9 varied among the animals within one group. On pulmonary CD4+ T 
cells, half of the animals in the control group (between 3.0 and 5.6%) and two of the animals 
from the BLM group (3.7% and 5.7%) showed a positive signal for CCR9. For all others, no 
CCR9 signal was detected. 
On CD8+ T cells CCR9 expression could be detected in most of the control samples (median 
4.3%, range 0.00-7.2%) and in 3 of the BLM samples (between 1.3% and 10%) (Figure 38a). 
A co-expression with CCR2 was not seen in the majority of the samples in which CCR9 
expression was observed (Figure 38b+c). Statistically, there was no difference in the relative 
content of CCR9+ T cells in the BLM and the control group. 
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Figure 38 CCR9+ T cells at day 12 after BLM treatment; a) CCR9+T cells within CD4+ or CD8+ T cells; b) 
CCR9+CCR2+T cells within CD4+ or CD8+ T cells; c) CCR9+CCR2+ T cells within total CCR2+ CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
 CCR10 5.5.8
CCR10 was only expressed on CD4+ T cells from control lungs with 1.3% (0.0-2%), but was not 
co-expressed with CCR2. For all other groups no CCR10 signal was obtained. 
 CXCR3 5.5.9
CXCR3 was expressed on 5.0% (2.8-9.7%) of CD4+ T cells from control lungs and on 7.7% (3.8-
11%) of CD4+ T cells. However, this increase was not statistically significant. CXCR3+CD8+ T 
cells represented 1.1% (0.00-4.2%) of pulmonary CD8+ T cells from control animals. In BLM 
mice, they amounted to 8.4% (0.00-15 %). The difference was also not statistically significant 
(p=0.07) (Figure 39a). 
In control mice, CXCR3 was not co-expressed with CCR2. Only in one sample double positive 
cells were found for both, CD4+ and CD8+ T cells (1.7% and 0.5%). Another sample showed 
some co-expression of CXCR3 and CCR2 only on CD4+ T cells (0.7%). In samples from BLM 
treated animals, the percentage of CXCR3+CCR2+ T cells was higher. 1.3% (0.30-2.2%) of CD4+ 
T cells were double positive. However, the difference to the control group was not 
significant (p =0.06). Within CD8+ T cells a co-expression between 0.7% and 2.8% was seen in 
4 of 7 samples (Figure 39b). 
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Calculated to CCR2+CD4+ T cells, 7.6% (1.9-14.7%) of cells expressed CXCR3, to CCR2+CD8+ 
cells this were 3.5% (0.00-11%) (Figure 39c). 
 
Figure 39 CXCR3+ T cells at day 12 after BLM treatment; a) CXCR3+T cells within CD4+ or CD8+ T cells; b) 
CXCR3+CCR2+ T cells within CD4+ or CD8+ T cells; c) CXCR3+CCR2+ T cells within total CCR2+CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
 CXCR4 5.5.10
4.1% (0.00-8.3%) of CD4+ T cells and 3.7% (0.80-5.4%) of CD8+ T cells from lungs of saline 
treated animals expressed CXCR4. Within CD4+ T cells from bleomycin treated mice, the 
fraction of CXCR4+ cells increased significantly to 7.2% (5.5-27%). Within CD8+ T cells from 
bleomycin treated mice 10% (0.15-16%) of the cells were CXCR4+, but the difference was not 
significant compared to control mice (Figure 40a). 
The co-expression with CCR2 was only weak. No CXCR4+CD4+ T cells were detected within 
pulmonary CD4+ T cells from control mice. Within CD4+ T cells from treated animals, double 
positive cells amounted to 0.7% (0.00-9%). Regarding the CCR2+CD4+ T cell population, 4.8% 
(0.00-45%) of the cells expressed CXCR4. Double positive cells represented 0.15% (0.00-
1.5%) of CD8+ T cells in control mice and 1.1% (0.00-7.2%) in BLM treated mice. Differences 
among control group and BLM group were not significant for both cell types (Figure 40b+c). 
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Figure 40 CXCR4+ T cells at day 12 after BLM treatment; a) CXCR4+ T cells within CD4+ or CD8+ T cells; b) 
CXCR4+CCR2+ T cells within CD4+ or CD8+ T cells; c) CXCR4+CCR2+ T cells within total CCR2+ CD4 or CD8 T cells; 
indicated p values obtained by Mann Whitney U test 
 CXCR5 5.5.11
CXCR5 was only rarely expressed on cells from control mice. On 0.30% (0.00-1.7%) of CD4+ T 
cells CXCR5 expression was detected. Within CD8+ T cells 0.70% (0.00-1.6%) expressed 
CXCR5. In lungs from BLM treated mice, this percentage increased significantly to 6.8% 
(0.00-10%) within CD4+ T cells and to 11% (2.3-17%) within CD8+ T cells (Figure 41a). 
In accordance with the general low expression, a co-expression with CCR2 was not found in 
control samples. In contrast, double positive cells amounted to 3.2% (0.00-5.7%) of CD4+ T 
cells and 6.0% (1.0-12%) of CD8+ T cells in samples from BLM treated animals (Figure 41b). 
Related to CCR2+CD4+ or CCR2+CD8+ T cells, CXCR5+CCR2+ cells represented 12% (0.00-19%) 
and 20% (7.2-36%) respectively (Figure 41c). 
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Figure 41 CXCR5+ T cells at day 12 after BLM treatment; a) CXCR5+ T cells within CD4+ or CD8+ T cells; b) 
CXCR5+CCR2+T cells within CD4+ or CD8+ T cells; c) CXCR5+CCR2+ T cells within total CCR2+ CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
 CXCR6 5.5.12
The fraction of CXCR6+ T cells did not differ significantly among the control group and the 
bleomycin treated group. CXCR6 was expressed on 2.4% (0.00-3.1%) of CD4+ T cells in 
control samples and on 2.9% (0.25-15%) in samples from the BLM group. On CD8+ T cells it 
amounted to 1.5 (0.00-1.9%) and 4.9% (0.00-11%) (Figure 42a). 
In control samples, no CCR2+CXCR6+ T cells could be detected, besides in one sample which 
showed 1% of double positive CD8+ T cells. In 3 BLM samples, double positive cells were 
between 2.2% and 5.9% of CD4+ T cells and between 1.9% and 4.9% of CD8+ T cells (Figure 
42b). This amounted to 15 to 31% CCR2+CXCR6+ cells of total CCR2+CD4+ T cells and 11 to 
15% of CCR2+ CD8+ T cells, respectively. One sample showed only double positive CD8+ T cells 
(0.4%), which relates to 4.2% of CCR2+CD8+ T cells. For the other 3 samples no CXCR6+CCR2+ 
cells were detected (Figure 42c). 
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Figure 42 CXCR6+ T cells at day 12 after BLM treatment, a) CXCR6+ T cells within CD4+ or CD8+ T cells; b) 
CXCR6+CCR2+T cells within CD4+ or CD8+ T cells; c) CXCR6+CC2R+T cells within total CCR2+ CD4+ or CD8+ T cells; 
indicated p values obtained by Mann Whitney U test 
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The pulmonary and systemic T cell responses following intratracheal bleomycin 
administration were analyzed using flow cytometry. On time points between 3 and 21 days 
after treatment the frequency of different T cell subtypes and CCR2 expression were 
investigated in spleen and lung of C57BL/6 mice. While there were no significant changes of 
the composition of the analysed T cell subtypes in the spleen after bleomycin treatment, the 
percentages of Tem, as well as of CCR2+ T cells increased in the lung. The maximum of 
CCR2+CD4+ T cell frequency was detected on day 12 after BLM treatment. At this time point 
co-expression of other chemokine receptors was examined.  
 Mouse model 6.1
For this work, a model of single intratracheal administration of 5U/kg bleomycin to C57BL/6 
mice was used.  
Bleomycin is not a single substance but a mixture of glycopeptide antibiotics produced by 
Streptomyces verticillus, first described in 1966 (70). It belongs to the group of antineoplastic 
antibiotics and is used for the therapy of different types of malignancies such as testicular 
cancer (71) and lymphoma (72). Bleomycin causes DNA single and double strand breaks 
which stops cell proliferation and results in cell death (73, 74). It shows distinct tissue 
specificity depending on the content of the so called bleomycin hydrolase, a cytosolic 
aminopeptidase within the tissue (75). This specificity might be responsible for the major 
advantage of BLM compared to most other anti-neoplastic drugs: the lack of 
myelosuppression and thus of immunodeficiency following BLM treatment. On the other 
hand, this results in BLM accumulation in tissues having a relative lack of bleomycin 
hydrolase, such as squamous epithelium and the lungs (76). This explains the tropism of the 
specific adverse effects of bleomycin like cutaneous and mucosal side effects and the 
development of diffuse interstitial pneumonitis, which occurs in approximately 10% of 
patients and is the dose limiting factor of bleomycin therapy (77). This pulmonary toxicity 
was used for induction of pulmonary fibrosis in animals for the investigation of mechanisms 
leading to interstitial lung diseases (78). 
The bleomycin model is a well characterized mouse model for ILD and the most commonly 
used one. It offers several advantages compared to other models for pulmonary fibrosis: the 
time for development of the fibrotic response, at least if the bleomycin is applied 
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intratracheally,  is shorter than in most other models like silica or irradiation induced fibrosis. 
It is easy to perform and does not need special equipment in contrast to irradiation or 
transgenic models. Another widely used model is the induction of the fibrotic reaction with 
the flourescent agent FITC. (79, 80) 
The FITC model was not suitable for this study since the agent can provide background 
staining. This would have limited the use of fluorocrome bound antibodies for FACS 
experiments used in the present study. 
However, the bleomycin model, like most animal models, is only partially able to simulate 
the pathological mechanisms of IPF. Although it represents some main histologic features of 
UIP, such as a mixed appearance of the lung tissue with fibrotic areas next to others with 
histological normal tissue and to a limited extend the histologic honeycombing, other typical 
patterns do not appear. The main histologic difference to the human disease is the location 
of fibrosis within the lung, which is mostly basal and subpleural in IPF but more peribronchial 
in the mouse model. Another important discrepancy is the lack of typically organized 
fibroblast foci in bleomycin induced pulmonary fibrosis. Furthermore, the bleomycin model 
initially shows a strong inflammatory reaction followed by the initiation of the fibrotic 
response which is not described for human IPF. (79, 80) 
The main point of criticism on the BLM mouse model is that it does not reflect the relentless 
progression seen in IPF. In contrast, the BLM induced fibrosis resolves 6 week after 
treatment (81). A clear disadvantage of this model is the considerable mortality during 
bleomycin treatment. 
Susceptibility to bleomycin induced fibrosis is different among mouse straines. BALB/c mice 
are not susceptible as they express bleomycin hydrolase. For this reason, we decided to use 
C57BL/6 mice which were previously found to be most susceptible to lung injury through 
BLM (82, 83). 
There is no standard protocol for the performance of this model. The bleomycin can be 
applied by intravenous, intraperitoneal, subcutanous or intratracheal injection and in 
different doses. The different aplication routes result in different localizations of the 
pulmonary lesions and a different timecourse for the development of fibrosis. Frequently 
used doses for intratracheal administration of bleomycin in mouse models differ between 1 
and 5 U/kg body weight (64, 84, 85). In the present study, a dose of 5 U/kg body weight 
bleomycin was chosen, as published previously (86).  
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 Mice with fibrotic disease show body weight loss but no systemic immune response 6.1.1
A loss of body weight is often seen in severe and systemic diseases. It is the result of an 
increased requirement for energy, especially in diseases with a high proliferation rate of 
distinct cell types like malignancies or inflammatory diseases. 
In accordance with previous publications, a body weight loss was detected in BLM treated 
mice (84, 87, 88). It showed a maximum at days 6 and 9.  
The change in T cell populations in the spleen as secondary lymphoid organ was examined as 
an indicator of an extra-pulmonary T cell response following intra tracheal BLM instillation. 
Neither the percentages of total CD4+ and CD8+ T cells nor in the composition of naïve CD4+ 
T cells, Tem, and Tcm changed during development of pulmonary fibrosis. About 2.1 % of CD4+ 
T cells and 1.2 % of CD8+ T cells in the spleen expressed CCR2. This percentage did not 
change significantly at any time point after bleomycin treatment. Thus, we did not find 
indications for a systemic T cell response following intra tracheal bleomycin administration.  
 T-cell kinetics in BAL and lung tissue during time course 6.2
 CD4+ and CD8+ T cells 6.2.1
The analysis of BAL is the standard method to evaluate cell and cytokine alterations in 
human pulmonary diseases (89, 90). The method is also frequently used in animal models for 
lung disorders, since this offers the possibility to compare the results with those in human 
disease in the same medium. 
Under physiologic conditions, human BALF contains about 85% alveolar macrophages and 
10% lymphocytes (91). As expected, very few lymphocytes were detected in saline treated 
control mice. Following treatment with bleomycin, the relative content of T cells increased, 
as well as total cell numbers. This is in accordance with previous publications, which found 
increased numbers of total cells and lymphocytes to a comparable extend by differential 
count of BAL cells (88, 92, 93). 
Of note, in BALF from BLM treated mice, levels of both, CD4+ and CD8+ T cells, were 
elevated, but in lung tissue the percentage of CD4+ T cells showed only a slight increase and 
the percentage of CD8+ T cells even decreased compared to control mice up to day 15.  
A previous study found a stronger increase of CD4+ T cells and also an increase of CD8+ T 
cells at days 3; 7 and 14 compared to control mice, although the percentage of CD8+ T cells 
on day 14 also tended to be decreased compared to day 3 or 7 (94). However, the results are 
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not fully comparable, as they calculated T cell percentages from total cells of a lung single 
cell suspension, whereas in the present study dead cells were excluded from the analysis. 
Furthermore, another report found stable percentages of CD4+ T cells in lungs of BLM 
treated mice during the disease course (95). 
Taken together, the results confirm an inflammatory reaction following BLM treatment. The 
somewhat contrary T cell kinetics in BAL and lung tissue might be due to a T cell migration to 
the airways or differential recruitment of T cells to the airways and the interstitial space. 
However, further studies are necessary to confirm and to explain this phenomenon. 
 Increase of effector memory T cells following bleomycin treatment in lung tissue 6.2.2
More important than the percentage of total T cells might be the content of different 
lymphocyte subtypes, as the kinetic of their composition during the time course allows 
drawing conclusions about the activation status, and thus indirectly about the role of the 
cells. 
Following the recognition of an antigen, naïve T cells expand and differentiate into effector T 
cells. Within one week, the majority of these effector cells will undergo apoptosis but a 
minor population will get further differentiated into memory cells. The memory T cell pool 
contains at least two subtypes; the central memory T cells (Tcm) and the effector memory T 
cells. Tcm are mostly found in secondary lymphoid organs. Tem emigrate to peripheral tissues 
for rapid response following recognition of a known antigen. During this development, T 
cells change the expression pattern of their surface molecules. (96-98) 
Naïve T cells express peripheral lymph node homing receptors like CD62L and CCR7, but do 
not express activation markers like CD44 or CD45RO. Following activation through an 
antigen, naïve T cells down regulate CD62L and up regulate CD44 (99). Expression of CD44, 
which is considered as memory or activation marker, can be used to separate naïve T cells 
from memory cells (100, 101). In addition, central memory T cells express CD62L and CCR7 
also found on naïve T cells (102). Effector memory T cells lack CD62L and CCR7, but gain 
expression of tissue specific homing receptors like CCR5 (103). 
In the present study, the kinetics of these CD4 T cell subtypes were examined as defined by 
the expression of the adhesion molecules CD62L and CD44. 
The main cell type in lung and spleen of control mice were CD62Lhi CD44low CD4+ T cells, and 
thus considered as naïve T cells. With a median of 75% versus 81% the percentage of naïve T 
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cells was slightly lower in lung than in spleen of saline treated controls. Following bleomycin 
treatment CD62LhiCD44lowCD4+ Tnaïve cells decreased while CD62LlowCD44hi Tem cells increased 
from 16% to a maximum of 31%. This might indicate either an activation of resident lung T 
cells or a recruitment of activated cells from the circulation to the lung as a response to the 
bleomycin induced lung injury. 
Similar results for CD62LhiCD4+ T cells and CD44hi CD4+ T cells in normal lung tissue were 
found in a study looking for migration of naïve T cells into various organs under steady state 
conditions in BALB/c mice (104). Another publication reported a population of about 70% 
CD3+CD44+ T cells in lungs of bleomycin treated animals, which did not change significantly 
between day 3 and 14 following BLM treatment. However, in controls the CD3+CD44+ T cell 
population was only 40% (94). Further, it is difficult to compare this study with the present 
results as there it is referred to total CD3+ cells, not to CD4+ T cells. 
Nevertheless, these results indicate that pulmonary T lymphocytes are activated after BLM 
application. This suggests that T cells might contribute to the initial pathogenesis of BLM 
induced pulmonary fibrosis. 
 CCR2+CD4+ T cells are increased and show CD62LlowCD44hi phenotype 6.2.3
The percentage of CCR2+ CD4+ and CD8+ T cells clearly increased during the first two weeks 
following BLM treatment with a maximum at day 12 and decreased again at the later time 
points paralleling the kinetic of the Tem subpopulation. 
Increased CCR2+ T cells were also found in BAL from paediatric ILD patients (68). In contrast, 
in BAL of Sarcoidosis patients, the CCR2 expressing population among CD4+ T cells was 
decreased (105). Furthermore, CCL2, the major ligand of CCR2, was increased in BAL of 
patients with different ILD, with BAL from IPF patients showing the highest levels (106-108). 
One study found that mice with artificial pulmonary overexpression of CCL2 were protected 
from mortality of bleomycin induced lung injury, while CCR2 deficiency abolished this 
protective effect. Surprisingly, they found increased numbers of lymphocytes and 
mononuclear cells in BAL of transgenic mice compared to WT mice (65). 
This observation contrasts previous publications, which claimed that CCR2 deficiency 
attenuates pulmonary fibrosis (64, 66, 67). 
In murine peripheral blood, CCR2 expression was found on the CD44+ T cell subpopulation 
but was nearly absent from CD44- T cells (62). Similar observations were made in human 
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peripheral blood, where CCR2 was predominantly expressed on CD45 RO+ effector memory 
cells (109). 
This differential expression pattern was also observed in the present study. The majority of 
the CCR2+CD4+ T cells exhibited CD62LlowCD44hi phenotype, thus belonged to the Tem 
subtype. With a percentage of 23% in control mice and 34% at day 12, CCR2+ cells 
represented a considerable fraction of pulmonary Tem cells. In spleen, the Tem subpopulation 
contained only 10 to 15% CCR2+ cells. In contrast CCR2 was expressed only in a minor 
population of CD62LhiCD44low Tnaive cells. 
The increase of CCR2+ CD4+ T cells and their affiliation to the Tem subtype indicates that they 
are a distinct population of activated cells. Although further investigation is needed to 
evaluate the specific role of these cells, it is likely that they play a role in the pulmonary 
immune response and the initiation of fibrogenesis in BLM induced pulmonary fibrosis in 
mice. 
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 Chemokine receptors 6.3
To obtain insight in the potential migratory capacity of the T cells we performed a 
comprehensive analysis of their chemokine receptor expression. For some chemokine 
receptors, antibodies for the flow cytometric analysis were not commercially available at the 
time point of this investigation. Therefore, some chemokine receptors like CCR1 and CXCR2, 
which were previously shown to play a role in pulmonary fibrosis, could not be taken into 
consideration (110, 111). 
 CCR6 6.3.1
The highest co-expression with CCR2 was observed for CCR7 and CCR6, whereas CCR7 was 
expressed on a similar percentage of T cells in control and BLM treated mice CCR6 was 
nearly absent on CCR2+ T cells of control animals but expressed on a median of 34 % 
CCR2+CD4+ T cells and of 20% CCR2+CD8+ T cells from treated mice. This was about two times 
higher than the percentage of T cells expressing CCR6 within total CD4+ and CD8+ T cells. 
CCR6 is frequently expressed on Th17 T cells (112, 113), an effector T cell subset that was 
shown to play a role in autoimmune diseases like rheumatoid arthritis or hashimoto’s 
thyreoiditis (114, 115). Furthermore, CCR6 expression was also found on a CD25+CD4+ T cell 
subpopulation. However, it was not restricted to these regulatory T cells. These CCR6+CD4+ 
cells expressed the memory marker CD44 and most of them presented a CD62Llow 
phenotype (116). Thus, like CCR2+ CD4+ T cells, they present a Tem phenotype.  
Unlike most other chemokine receptors, only one chemokine, CCL20, is known to bind to 
CCR6 (117). CCL20 was found to be produced by human pulmonary epithelial cells in vitro 
(118). It mediated migration of CD4+ T cells (119), as well as of blood derived dendritic cells 
in vitro (118). There are several reports about specific functions of CCR6+ T cells in the lung. 
CCR6+ T cells were highly enriched in BAL of asthmatic patients compared to peripheral 
blood (120).  
One study investigated the CCR6 expression on T cells from atopic patients with active 
allergic rhinitis and non-atopic healthy controls. CCR6+ T cells were enriched among T cells 
derived from nasal mucosa, lung, skin and BAL compared to peripheral blood derived T cells. 
There was no difference between atopic patients and the control group. Therefore, they 
suggested a role of CCR6 in the recruitment of T cells to the airways under steady state 
conditions. (121)  
69 
Discussion 
In a COPD mouse model, CCR6+ lymphocytes and levels of other CCR6 expressing cells were 
increased following cigarette smoke exposure for four weeks. In turn, CCR6 deficient mice 
showed less increase of dendritic cells, neutrophils and lymphocytes in BAL compared to 
wild type mice (122). 
In human sarcoidosis, CCR6 expression on CD4+ T cells was increased in BAL from patients 
with active disease, whereas CD8+ T cells were CCR6- (119). Another study investigated 
chemokine production and chemokine receptor expression on lymphocytes from blood of 
patients suffering from systemic sclerosis. The frequency of CCR6+CCR10-CD4+ T cells 
correlated with IL-17 and IL-22 producing T cells. Patients with associated ILD presented 
higher IL17 and IL-22 producing cells compared to patients without ILD, which gives evidence 
for a role of these cells in scleroderma associated pulmonary fibrosis (123). 
An immunohistological study found higher CCR6 in lungs of IPF patients compared to control 
lungs. However, it was seen on epithelial sites but not on lymphocytes, this might indicate a 
role of CCR6 in idiopathic pulmonary fibrosis (124). 
As described above, there is evidence for a role of the CCR6/CCL20 axis in the lymphocyte 
recruitment to the airways in different diseases as well as under physiological conditions.  
CCR6 was clearly expressed on a higher percentage of CCR2+ T cells than on total CD4+ or 
CD8+ T cells. This could indicate a preferential recruitment of CCR2+ T cells to the lung in 
bleomycin induced fibrosis. The high co-expression of CCR6 and CCR2 might also be a hint 
towards an enhanced Th17 polarization of CCR2+CD4+ T cells. The presence of CCR6 on 
CD25+ regulatory T cells, mentioned above, is also in accordance with the hypothesis of 
regulatory functions of CCR2+ T cells. However, this observation needs further functional 
investigation of these cell populations such as the analysis of their cytokine production. 
 CCR7 6.3.2
CCR7 is expressed on different subsets of lymphocytes and mature dendritic cells. It is 
necessary for leukocytes migration to secondary lymphoid organs through high endothelial 
venules. Thus, its ligands CCL19 and CCL21 are preferentially expressed in lymphoid tissue, 
but also on gastrointestinal sites, kidneys and lungs (125). 
CCR7 deficient mice accumulated T cells in the periphery; in consequence they were reduced 
in the secondary lymphoid tissues. Further, CCR7 deficiency caused impaired lymph node 
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architecture, whereas formation of tertiary lymphoid tissue in the intestinal tract and the 
airways was still possible (126). 
In human blood CCR7 was expressed on nearly all CD62L+CD27+CD4+ T cells, representing the 
naïve and the central memory T cell population. However, CCR7 expression itself does not 
define a distinct subset as it is also expressed to a lower extend on cell populations lacking 
CD62L, CD27 or both of them. On CD8+ T cells, CCR7 was found to be expressed on all naïve 
cells defined by the expression of CD45RA and CD27, to a lower amount on memory cells 
(CD45RA-CD27+) and nearly absent from effector cells (CD45RA+CD27-) (127). 
Th1 and Th2 cell lines up regulated CCR7 following in vitro stimulation with CD3 (103), 
whereas CD25+CD4+ Treg cells from human peripheral blood down regulated CCR7 and up 
regulated CCR4 upon allergen stimulation (128). 
There are some reports about an involvement of CCR7 in the context of pulmonary fibrosis. 
CCR7 was overexpressed in fibrotic regions of lung biopsies from patients with UIP compared 
to NSIP and RBILD. However, CCR7 expression determined by immunohistology was found in 
all three groups, but not in normal tissue from cancer patients. CCR7 was partly co-localized 
with CD45, thus expressed on leukocytes and not with aSMA, indicating no CCR7 expression 
on fibroblasts. (129) 
Bleomycin induced fibrosis was attenuated in CCR7 deficient mice. These mice showed 
organized formation of BALT, which was absent in wild type mice, and a specific 
accumulation of CD4+CD25hiFoxP3+ Treg cells. (95) 
The proportion of CCR7+ T cells did not change following BLM treatment, neither to total 
CD4+ or CD8+ T cells, nor to CCR2+CD4+ or CCR2+CD8+ T cells. Clearly, in this study CCR7 
expression was not restricted to the Tnaive subpopulation, as it was expressed on a high 
percentage of CCR2+CD4+ T cells which exhibited predominantly Tem phenotype. 
When taking CCR7 as surrogate parameter for the lymph node homing capacity, it suggests 
that a considerable population of pulmonary T cells keep the capability to enter the lymph 
node even if they change the phenotype towards Tem cells following BLM treatment. This 
might also demonstrate that the borders between the different T cell subsets are not 
completely fixed, but there exist overlapping phenotypes. 
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 CCR3 and CCR4 6.3.3
CCR3 was found mainly on eosinophils as well as on basophils and T cells. It has several 
ligands, the most well-known being eotaxin 1-3 (CCL11, 24, 26) but also others like MCP 2-4 
(CCL7, 8, 13) and RANTES (CCL5) (130). 
CCR4 is expressed on T cells, NK cells and basophils. Several chemokines bind to CCR4 like 
TARC, MDC and MIP-1β. CCR3 and CCR4 are considered to be preferentially expressed on 
Th2 lymphocytes (131, 132). 
In the lung, CCR3 and CCR4 were mainly investigated in the context of the classical Th2 
associated disease asthma. They were both predominately, but not exclusively, expressed on 
IL-4 producing cells in BAL and blood from asthmatic patients, as well as from healthy 
controls (133). CCR4, but not CCR3 was expressed on T cells from transbronchial biopsies of 
asthmatic patients, and allergen challenged asthmatics had significantly higher CCR4+ CD4+ T 
cells (134). 
Furthermore, CCR3 might play a role in the pulmonary response to chronic exposure to 
irritants, since CCR3+CD8+ T cells as well as total CCR3+ T cell population was increased in BAL 
of COPD patients and smokers compared to non-smokers (135). 
There are several reports about an involvement of CCR3, CCR4 and their ligands in extra-
pulmonary and pulmonary fibrotic diseases. CCR3 ligands, CCL11 and CCL5 were increased in 
patients with idiopathic retroperitoneal fibrosis and various CCR3 expressing cell types 
including lymphocytes were found in the fibrotic lesions (136). In a study with patients 
suffering from sarcoidosis or exogen allergic alveolitis (EAA), CCR3 expression on BAL CD4+ T 
cells correlated with HRCT score and reduced TLco in the EAA group which showed partly 
histological UIP pattern (137). CCR4+CD4+ T cells were increased in BAL of children with ILD 
compared to the control group (68). Furthermore, IPF patients showed higher CCR4+CD4+ T 
cells in BAL compared to patients with other ILD and healthy controls. In these patients the 
proportion of CCR4+CD4+ T cells was higher in BAL than in blood (138). The mRNA levels of 
the CCR4 ligands CCL17 and CCL22 were increased in lung tissue from bleomycin treated 
mice at time points up to 20 days following treatment. Neutralization of CCL17 attenuated 
the fibrotic response (139). Hence, especially CCR4 seems to have an active role in 
experimental as well as in human pulmonary fibrosis. 
Our results showed a significant increase of CCR3 and CCR4 expressing T cells within total 
CD4+ T cells as well as within the CCR2+CD4+ T cell subpopulation on day 12 after BLM 
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treatment. This observation might indicate an enhanced Th2 polarization of CD4+ T cells in 
bleomycin induced pulmonary fibrosis. Of note, CCR4 expression was absent on pulmonary 
CCR2+ T cells from saline treated mice, but was found following bleomycin treatment. Thus, 
CCR2+ T cells seem to selectively express CCR4 upon activation through the BLM induced 
lung injury. Notably, in BLM treated mice, the percentage of CCR3 and CCR4 expressing cells 
was higher within the population of CCR2+CD4+ T cells than within total CD4+ T cells. This 
preferential expression of the Th2 associated markers on CCR2+ T cells might be an 
indication for specific functions of these cells in the T cell response to bleomycin treatment. 
However, the Th2 phenotype of these cells still needs to be confirmed by assessment of 
their cytokine production. 
 CXCR5 6.3.4
CXCR5+CD4+ T cells were suggested to define a distinct subset of B helper T cells which are 
found in the B cell zone of lymphoid tissue germinal centres, called follicular helper T cells 
(TFH) (140, 141). This T cell subset was recently described, and their categorization within the 
different T cell populations is not fully clarified yet (142). 
The main function attributed to CXCR5+ T cells is an evident role for the migration of T cells 
to the B cell zone and in the regulation of the antibody production by B cells (143, 144). So 
called circulating TFH cells were found in human chronic hepatitis virus B and C infection (145, 
146). CXCR5+CD4+ T cells were also increased in liver and spleen of HBV transgenic mice 
(145). These cells co-expressed CCR7 and CD62L in contrast to their relatives in lymphoid 
tissue and induced Ig production from B cells (144, 147). A study using CXCR5 deficient mice 
showed that CXCR5 was needed for the formation of tertiary lymphoid tissue (tLT) during H. 
pylori infection and CXCR5 deficiency resulted in impaired antibody response to H pylori 
(148).  
These circulating TFH cells were also shown to be increased in peripheral blood of patients 
with distinct autoimmune diseases like severe systemic lupus erythematodes (149) and 
primary Sjögren’s Syndrome (150). In patients with primary Sjögren’s Syndrome, a 
subpopulation of CCR6 expressing Th17 like TFH cells was increased (150). However, in the 
present study co-expression of CCR6 and CXCR5 was not assessed, expression of both 
receptors increased after BLM treatment. Furthermore, both receptors were expressed on 
pulmonary CCR2+ T cells from BLM treated mice, but not from control mice. 
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In human lung tissue samples of patients suffering from idiopathic pulmonary hypertension, 
CXCR5+CD4+ T cells were found in peri-arterial tLT, and the level of CXCR5+CD4+ T cells was 
decreased in peripheral blood of these patients (151). Thus, there are hints for a role of 
these cells in pulmonary diseases which offer approaches for further investigation of their 
functions. 
Within pulmonary CD8+ T cells of BLM treated mice, CXCR5 expressing cells were even more 
frequent as within CD4+ T cells. CXCR5+CD8+ T cells are not very well described, yet. These 
cells were found in the B cells zone of tonsil lymphoid tissue and, to a lower extend in 
peripheral blood of patients undergoing routine tonsillectomy. They expressed activation 
markers like CD45RO and did not express CCR7. Consequently, they were classified as 
effector memory cells. Furthermore, tonsil CXCR5+CD8+ T cells co-expressed CCR5 (152, 153). 
On the other hand, CXCR5 and CCR7 were upregulated in cell lines following TCR stimulation 
in vitro (103). 
 CCR5 6.3.5
CCR5 is commonly considered as a Th1 related chemokine receptor together with CXCR3 
(132). However, there is growing evidence that the expression of these chemokine receptors 
is not strictly limited to Th1 or Th2 cells in vivo (154). 
In humans, CCR2 is strongly co-expressed with CCR5 (109), and the two receptors were 
shown to form heterodimers upon activation (155). CCR5 expression on peripheral blood T 
cells was shown to be similar in mice and humans. However, its expression differed on other 
cell types. It was more expressed on CD8+ T cells than on CD4+ T cells in peripheral blood 
(56). 
CCR5 is well known for its role in HIV infection (156-158), but it also played a role in several 
inflammatory diseases such as multiple sclerosis (61). CCR5 expression on CD8+ T cells from 
resected human lung tissue was shown to correlate with disease severity of COPD (159). 
CCR5 expressing CD4+ and CD8+ T cells were highly enriched in BAL of asthmatic patients 
compared to peripheral blood (120). In a mouse model of ovalbumin induced asthma, CCR5 
deficiency attenuated airway hyper responsiveness and goblet cell metaplasia (160). In a 
mouse model of viral challenge, CCR5+CD8+ T cells were rapidly recruited to the lung airways 
(161). Mice deficient for CCR5 or CCL3, a ligand for CCR5, showed attenuated pulmonary 
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fibrosis trough impairment of fibrocyte accumulation and macrophage migration (162). 
However, this effect could not be shown in another publication (66).  
CCR5 expression was virtually absent from pulmonary CD4+ T cells from control mice and 
bleomycin treated ones. On CD8+ T cells CCR5 expression was also not detected in control 
lungs but increased after bleomycin instillation. On CD8+ T cells CCR5 showed also a co-
expression with CCR2 to a variable extend. The lack of CCR5 expression on pulmonary CD4+ T 
cells from treated mice might vote against a Th1 response to the bleomycin treatment. 
 CXCR4 6.3.6
On human T cells, CXCR4 is expressed on naïve populations (132, 163). In mice, no 
preferential expression on subtypes was found and expression on peripheral blood 
lymphocytes was evidently lower than in humans. CXCR4 on murine cells increased following 
stimulation with phytohaemagglutinin. On human cells, it decreased first, and then 
increased from day 2 on. CXCR4 expression on CD8+ T cells but not on CD4+ T cells increased 
in secondary lymphoid tissue following antigen challenge. (164) 
CXCR4, like CCR5, was shown to act as co-receptor of HIV-1 entrance to lymphocytes (165). 
A high number of CXCR4 expressing T cells was found in human renal allograft rejection 
(166). This implicates a possible role in non-infectious inflammatory diseases. 
The level of CXCR4 ligand CXCL12 (SDF-1) was increased in murine lungs following BLM 
administration during the first week after treatment whereas CXCR4 expression was 
increased from day 3 to 21. Blockade of CXCR4 resulted in lower collagen deposition in the 
lungs of bleomycin treated mice (167, 168). However, this effect was mainly attributed to 
the impairment of the recruitment of bone marrow derived mesenchymal stem cells 
(BMDMSC), so called fibrocytes, which express CXCR4 and are attracted to the lung following 
BLM treatment and may differentiate into fibroblasts (35, 169). 
CXCL12 gene expression was upregulated in lungs of patients suffering from IIP. However, 
CXCR4 gene expression did not differ significantly among diseased and healthy patients. 
Immunohistological studies suggested macrophages as the main source of CXCL12 in IIP. 
Furthermore, in CXCR4+/- mice collagen content was decreased, although these mice showed 
higher contents of lymphocyte in BAL (170). 
About the role of T cells expressing CXCR4 in the context of chronic lung diseases, there is 
not much known. In fact, the levels of CXCR4+CD4+ T cells were increased in BAL of patients 
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with chronic hypersensitivity pneumonitis when comparing patients with subacute 
hypersensitivity pneumonitis and healthy controls. (171). 
The percentage of CXCR4+ cells increased within CD4+ T cells following BLM treatment. 
Within CD8+ T cells, the increase was not statistical significant. Co expression with CCR2 was 
stronger on CD8+ T cells. However, some samples also showed very high co-expression on 
CD4+ T cells. The significance of this increase is difficult to evaluate as there is not much 
known about the function of CXCR4+ T cells and, as mentioned above, evident differences 
exist among the species. 
 CCR9 and CCR10 6.3.7
CCR9 was only expressed on a minor population of T cells and was not co-expressed with 
CCR2. Furthermore, no difference in CCR9 percentages could be observed between BLM 
treated mice and control mice. These findings are in line with the attributed function of 
CCR9 as a specific homing receptor to intestinal sites playing a role for example in 
inflammatory bowel diseases (172-174). CCR9 was found to be important for the migration 
of Treg to the intestine in mice under healthy conditions (175). Furthermore, it played a role 
in T-cell development in the thymus (176). 
In the lung, no expression was observed on human lung homogenates from non-asthmatic 
and asthmatic donors (177). 
In contrast, CCR10 plays a role in migration of distinct lymphocytes to the skin (178), and 
through this, it is involved in contact hypersensitivity (179). 
In a study investigating the role of regulator of g protein signalling 16 (RGS16) in T cells 
trafficking, CCR10 expressing T cells were found in the lungs of Rgs16-/- mice following 
challenge with S. mansoni, but only to a minor extend in wild type mice (180). This finding 
might suggest a specific role of CCR10 in lymphocyte recruitment to the lung during 
infection. 
However, in the present study, CCR10 was nearly absent on lung lymphocytes from saline 
and BLM treated mice, voting against a specific role of CCR10+ T cells in bleomycin induced 
pulmonary fibrosis. 
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 CXCR6 6.3.8
CXCR6 was described as chemokine receptor responsible for lymphocytes homing to the 
lung as well as their retention in the lung. It was preferentially expressed on Th1 
effector/memory T cells (181). Its ligand CXCL16 was constitutively expressed on human 
bronchial epithelial cells (182). 
Antigen specific CD8+ or CD4+ T cells expressing CXCR6 increased in BAL and lung of mice 
immunized intranasally with recombinant tuberculosis antigen expressing adenovirus, or 
recombinant antigen respectively, but not in mice immunized subcutaneously. Mice 
receiving antigen and CXCL16 before infection with M. tuberculosis, and thus presenting 
higher CXCR6+CD8+ T cell numbers, could significantly decrease the pathogen burden. (183) 
CXCR6 expression on CD8+ T cells from lung tissue of COPD patients correlated with the 
disease severity. However, levels of CXCL16 were equally high in the different stages (159). 
CXCR6+ T cells were enriched in human BAL from patients with sarcoidosis compared to 
peripheral blood. Furthermore, the count of CXCR6+ T cells in BAL was higher in ILD and 
Sarcoidosis patients than in healthy control patients and asthmatic patients (184). In lung 
filtrates CXCR6 was highly expressed on a T-cell subset expressing CD103, a late activation 
marker, but not on early activated CD69- T cells (185). This indicated an involvement of 
CXCR6+ T cells in different interstitial lung diseases. 
Despite these reports about specific functions of CXCR6+ T cells in the lung the current 
results did not show significant differences in the percentage of pulmonary CXCR6 
expressing T cells among saline and BLM treated mice. However, especially among the 
samples of treated mice the proportion of CXCR6+CD4+ T cells was not homogenous. In some 
samples CXCR6+ T cells represented a considerable population; in others no CXCR6 
expression could be detected. In the samples which showed CXCR6 expression, it was also 
frequently co-expressed with CCR2. For a valid statement about these changes a higher 
number of samples would probably be necessary, but the differences in the CXCR6 
expression among the samples could be an indicator of the different capability of the 
animals to react to the BLM induced lung injury. 
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 CXCR3 6.3.9
CXCR3 was found to be preferentially expressed on Th1 polarized T cells (132, 181). 
On murine CD8+ T cells, it was expressed on most activated cells (186). In one study on 
murine B. bronchiseptica infection, concentrations of CXCR3 ligands I-TAG (CXCL11), MIC 
(CXCL9), and IP-10 (CXCL10) were increased and resulted in leucocyte migration to the lung 
(187). A study examining chemokine receptor expression in BAL and peripheral blood of 
asthmatic patients found higher CXCR3 expression on BAL cells than on cells from peripheral 
blood. The concentration of CXCR3 ligands increased following segmental allergen challenge, 
while CXCR3 surface expression decreased most likely through receptor internalization (120). 
CXCR3 deficient mice showed increased mortality and more severe fibrotic reaction 
following BLM treatment. In the same study, lower lymphocyte numbers were detected in 
CXCR3 deficient animals 7 days after BLM treatment, but no difference for other 
inflammatory cells (85). This also gives hints to a role of CXCR3 in lymphocyte recruitment to 
the lung airways. 
However, in BAL of patients with IPF, lower expression of CXCR3 on CD4+ T cells was found 
compared to non-IPF, sarcoidosis, and control patients and higher CXCR3 expression on CD4+ 
T cells in peripheral blood. Notably, they found higher CXCR3 expression on BAL lymphocytes 
when patients were treated with glucocorticoids. Lower CXCR3 expression correlated with a 
decrease of total lung capacity and vital capacity as well as an increase of in alveolar-arterial 
pO2 difference 6 to 12 months later. (138) 
For CXCR3 no difference among control and BLM group could be detected. However, within 
CD8+ T cells, there was a trend towards a higher percentage of CXCR3+ cells but did not reach 
statistical significance. Together with the lack of CCR5 expression on CD4+ T cells the stable 
CXCR3 expression votes against a Th1 polarization following BLM treatment. 
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 Conclusion 6.4
This project aimed a phenotypic characterization of CCR2+ T cells in an animal model of 
bleomycin induced pulmonary fibrosis as basis for further functional analysis of these cells. 
First of all, the percentages of CCR2+ T cell were increased in murine lungs following BLM 
treatment. This leads to the question if these cells have a specific role in the disease course 
in this model. Although no functional assessment was performed here, the predominant 
affiliation of CCR2+ to the Tem suggests an active participation of T cells in BLM induced 
pulmonary fibrosis. The peak of the relative content of CCR2+ T cells was at day 12, thus in 
the beginning of the fibrotic phase of bleomycin induced fibrosis. This could lead to two 
different speculations: CCR2+ T cells could play a role in the initiation of the fibrotic 
response; or CCR2+ T cells could be a reaction of the immune system in order to limit the 
fibrotic response. 
However, the differences in chemokine receptor co-expression among control group and 
BLM treated mice suggests that CCR2+ T cells are not a static population with a defined 
phenotype, but can regulate the surface expression of these receptors in response to 
alterations of the (patho-) physiological conditions.  
Taking chemokine receptor expression as indicator for the assignment to different CD4+ T 
cell subsets, CCR2+CD4+ T cells from lungs of BLM treated mice showed increased 
proportions of three different subpopulations. The increased percentage of CCR3+ and CCR4+ 
cells indicated a subpopulation of Th2-like cells within the CCR2+ CD4+ T cell population. 
Whereas, the markedly increased amount of CCR6+ cells suggests a Th17 phenotype of a 
large group of CD4+ T cells. The third subset was the TFH population, defined by the 
expression of CXCR5, which was perhaps the most surprising finding. 
Further studies are necessary to reveal the functional potential of these cells. To prove the 
polarization of the different subsets, it will be necessary to test the production of the 
respective cytokines. Furthermore, the regulatory function needs to be proven by the 
assessment of classical Treg marker like CD25 and FoxP3 as well as in functional assays. The 
relevance of these findings for the human disease needs to get investigated in analogous 
studies in human samples.  
Nevertheless, the results of this study strengthen the hypothesis that there is a specific role 
of CCR2+ T cells in murine BLM induced pulmonary fibrosis. The understanding of this role 
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might give further insight into the pathogenic processes of ILD and provide new targets for 
therapeutic approaches. 
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Interstitial lung diseases (ILD) are severe chronic lung diseases characterized by an increased 
deposition of extracellular matrix in the lung interstitial space, leading to a thickening of the 
alveolar walls and impairment of the gas exchange. One of the most common entities in this 
category is idiopathic pulmonary fibrosis (IPF) with a mean survival time of 2 to 3 years from 
diagnosis. Until now, there is no curative therapy available and the symptomatic anti- 
inflammatory treatment and oxygen supplementation cannot prevent the development of 
the end stage pulmonary fibrosis. 
The chemokine receptor CCR2 is important for leukocyte recruitment to inflamed tissues 
through interaction with CCL2 (MCP-1). The blockade of the CCR2/CCL2 pathway attenuated 
the development of pulmonary fibrosis in mouse models. However, CCR2+ T-lymphocytes 
acquired regulatory functions in experimental arthritis during the course of disease. 
Therefore, it is unknown whether CCR2+ T cells are involved in the pathogenesis of IPF or, on 
the contrary, represent an unsuccessful effort of the immune system to limit the disease.  
Observations in paediatric patients with different forms of ILDs suggested a role for CCR2+ T 
cells in pulmonary fibrosis. 
To characterize these T cells, flow cytometric studies were performed using the bleomycin 
mouse model of pulmonary fibrosis. The kinetic of CCR2+ T cells in BALF, lung tissue, and 
spleen following intratracheal administration of bleomycin (BLM) was assessed at time 
points between day 3 and day 21. To determine, if the constellation of naïve, central 
memory and effector memory T cells changes after BLM treatment, and to which of these 
subtypes  CCR2+ T cells belong to, the cells were additionally stained for CD62L and CD44. 
For further characterization of CCR2+ T cells, chemokine receptor co-expression with CCR2 
was investigated at the time point of the maximal presence of CCR2+ T cells. 
Total T cell numbers increased in BAL and lung tissue but not in spleen. Percentages of 
CD62LlowCD44hi effector memory T cells increased in lung tissue in the early phase of BLM 
induced fibrosis, while the CD62LhiCD44low naïve T cell population decreased. 
The percentage of CCR2+ T cells increased following BLM treatment with a maximum on day 
12. The majority of CCR2+CD4+ T cells showed a Tem phenotype.  
CCR3, CCR4, CCR6, CXCR4, and CXCR5 expressing cells increased within the pulmonary CD4+ 
T cell population following bleomycin treatment. Among CD8+ T cells from treated mice, 
81 
Summary 
CCR5, CCR6, and CXCR5 positive cells were increased. CCR7 was highly co-expressed with 
CCR2 in saline and bleomycin treated mice, whereas co-expression of CCR3, CCR4, CCR6 and 
CXCR5 increased significantly in treated mice. 
The results indicate an activation of pulmonary T cell populations following bleomycin 
treatment. CCR2+CD4+ T cells probably take part on this T cell response as they exhibit an 
effector memory phenotype and increase following BLM treatment. In contrast, the stable 
percentages of the different T cell subtypes in spleens gave no hint for a systemic T cell 
reaction. 
The pattern of chemokine receptor expression argues against a Th1 polarization and towards 
a Th2, Th17 or TFH polarization of CCR2+ T cells. 
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Interstitielle Lungenerkrankungen (ILD) bilden eine Gruppe schwerer chronisch 
progredienter Lungenerkrankungen. Sie sind gekennzeichnet durch die vermehrte Bildung 
extrazellularer Matrix im Interstitium der Lunge, welche zu einer Verdickung der 
Alveolarwände und damit einer Gasaustauschstörung führt. Die häufigste Erkrankung dieser 
Gruppe ist die Idiopathische pulmonale Fibrose (IPF). Die mittlere Überlebenszeit von IPF 
Patienten liegt bei etwa 2 bis 3 Jahren nach Diagnosestellung. Bis heute gibt es keine 
kurative Therapie und die symptomatische Therapie mit anti-inflammatorischen 
Medikamenten und Sauerstoff kann das Fortschreiten der Erkrankung nicht verhindern. 
Der Chemokinrezeptor CCR2 spielt eine wichtige Rolle bei der Migration von Leukozyten in 
entzündete Gewebe, durch Interaktion mit dessen Liganden CCL2 (MCP-1)  
Die Blockade der CCR2/CCL2 Achse konnte im Mausmodell die Entwicklung einer 
Lungenfibrose verringern. Andererseits wurde in einem Mausmodell für Rheumatoide 
Arthritis gezeigt, dass CCR2+ T-Zellen regulatorische Funktionen zeigen können. Somit ist 
unklar, ob CCR2+ T-Zellen an der Pathogenese der Lungenfibrose beteiligt sind, oder einen 
erfolglosen Versuch des Immunsystems darstellen, die Krankheit einzudämmen. 
Beobachtungen bei Kindern mit verschiedenen Formen interstitieller Lungenerkrankungen 
legen eine Funktion von CCR2+ T-Zellen bei Lungenfibrose nahe. 
Um diese Zellen näher zu charakterisieren wurden durchflusszytometrische Untersuchungen 
am Bleomycin Mausmodel für Lungenfibrose durchgeführt. 
Die Veränderungen des prozentualen Anteiles von CCR2+ T Zellen in BAL, Lungengewebe und 
Milz wurden an Zeitpunkten zwischen Tag 3 und Tag 21 nach der Behandlung mit Bleomycin 
untersucht. Zusätzlich wurde die Expression von CD62L und CD44 bestimmt, um zu 
untersuchen, ob sich das Verhältnis von naiven, effector memory, und central memory T-
Zellen nach der Behandlung mit Bleomycin ändert und zu welchen der Subtypen die CCR2+ T-
Zellen gehören. Zur weiteren Charakterisierung wurde die gleichzeitige Expression anderer 
Chemokinrezeptoren zu dem Zeitpunkt bestimmt, an dem der höchste Anteil an CCR2+ T-
Zellen gemessen wurde. 
In der BAL und im Lungengewebe stieg der Anteil von T-Zellen an, während sich in der Milz 
keine Veränderungen zeigten. In der Lunge stiegen die CD62LlowCD44hi effector memory T-
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Zellen in der frühen Phase der BLM induzierten Fibrose an, während die CD62LhiCD44low 
naiven T-Zellen absanken. Die Milz zeigte auch hier keine Veränderungen. 
Auch die CCR2+ T-Zellen stiegen nach der Behandlung mit BLM an und zeigten ein Maximum 
an Tag 12. Die Mehrzahl der CCR2+CD4+ Zellen gehörten zu den effector memory T-Zellen. 
Im Vergleich zur Kontrollgruppe fanden sich in der Lunge von Bleomycin behandelten 
Mäusen vermehrt CD4+ T-Zellen, die die Chemokinrezeptoren CCR3, CCR4, CCR6, CXCR4 und 
CXCR5 exprimierten. Innerhalb der CD8+ Zellpopulation waren CCR5, CCR6 und CXCR5 
häufiger exprimiert. CCR7 war sowohl in der Kontrollgruppe, als auch bei behandelten 
Mäusen am häufigsten gleichzeitig mit CCR2 exprimiert. Der Anteil an CCR3, CCR4, CCR6 und 
CXCR5 exprimierenden CCR2+ Zellen stieg nach Behandlung mit Bleomycin signifikant an. 
Die Ergebnisse legen nahe, dass pulmonale T-Zellen in Folge der Bleomycinbehandlung 
aktiviert werden. Da CCR2+ T-Zellen einen erheblichen Anteil dieser aktivierten Zellen 
ausmachen, scheint es wahrscheinlich, dass diese eine wichtige Rolle im Rahmen der T-
Zellreaktion spielen. Im Gegensatz dazu fanden sich keine Hinweise auf eine systemische  
Reaktion des T-Zellsystems in den Proben aus der Milz. 
Die Konstellation der exprimierten Chemokinrezeptoren spricht gegen eine Th1 Polarisierung 
der CCR2+ T-Zellen. Vielmehr zeigten sich Hinweise für eine Th2, Th17 oder TFH 
Differenzierung. 
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